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ABSTRACT 
 
Purpose:  The primary purpose of this investigation was to determine if age is 
associated with blood markers of inflammation (C-reactive protein [CRP]) and 
fibrinolysis (fibrinogen, tissue plasminogen activator [t-PA], and plasminogen 
activator inhibitor – 1 [PAI-1]), independent of body fat and physical activity 
levels.   
Methods:  A total of 40 healthy males and 42 healthy females ranging in age 
from 21 to 89 years participated in this cross-sectional study.  Blood levels of 
CRP, fibrinogen, t-PA, and PAI -1 were measured and compared with age, 
clinical characteristics, physical activity levels, and body composition.  Body 
composition was assessed with dual-energy x-ray absorptiometry and physical 
activity was assessed with a StepWatch Activity Monitor.   
Results:  Age was not associated with concentrations of CRP (r = -0.073, p = 
0.519).  CRP was significantly correlated (p < 0.05) to HDL levels (r = -0.255), 
BMI (r = 0.304), percent body fat (r = 0.221) and trunk fat mass (r = 0.234).  Of 
these, BMI was the only significant predictor (r2 = 0.095, p = 0.002) of CRP 
levels.  Age was not correlated with fibrinogen (r = 0.206, p = 0.065), or PAI-1 (r 
= 0.084, p = 0.454), but was initially correlated with t-PA (r = 0.228, p = 0.042).  
The markers of fibrinolysis were correlated (p < 0.05) with blood pressure, HDL, 
triglycerides, percent body fat, body fat mass, percent trunk fat, and trunk fat 
mass.  However, none of these variables or age were independent predictors of 
 x
blood concentrations of fibrinogen (r2 = 0.237, p = 0.226), t-PA (r2 = 0.079, p = 
0.636), or PAI – 1 (r2 = 0.137, p = 0.333).   
Conclusions:  The primary finding of the current study is that age is not 
independently associated with blood concentrations of CRP, fibrinogen, tPA or 
PAI-1.  However, it was observed that inflammation and fibrinolysis were 
associated with blood pressure, cholesterol levels, and measures of body fatness.  
These associations provide a possible explanation for the discrepancy between our 
findings and those of previous studies which did not control for such factors.   
 
 xi
 
 
CHAPTER ONE 
 
INTRODUCTION 
 
 
 
 Cardiovascular disease (CVD) has been and remains the leading cause of 
death in the United States over the last century, claiming nearly 700,000 lives 
annually in the United States (U.S.) (6).  Over 27 million of the 71.3 million 
known cases of cardiovascular disease are found in adults 65 years of age or older 
(147), which is a reflection of the increased risk for CVD associated with aging 
(5,22,130).  Over the last decade, evidence suggests that chronic, low-grade 
inflammation is an underlying component in the initial development and 
progression of atherosclerosis and an independent risk factor of cardiovascular 
disease (43,114,130).  C-reactive protein (CRP), a hepatocyte-derived acute-phase 
protein (21,22), is the most commonly studied marker of inflammation, and is 
clearly related to the incidence of atherosclerosis and acute coronary syndrome 
(12,97,101,111,130).  CRP initiates production of inflammatory cytokines such as 
tumor necrosis factor - alpha [TNF-α] and interleukin-6 [IL-6] (48,95) and 
mediates monocyte and macrophage infiltration into endothelial tissue (79).  
Consequently, CRP is considered to be the “golden marker” for chronic, low-
grade inflammation (97).  
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 Fibrinogen is another acute-phase protein that is often considered to be a 
marker of inflammation (11), but is actually a determinant of blood viscosity and 
an important factor in the formation of a blood clot (thrombosis) in the blood 
vessel (41,42).  Fibrinolysis is a natural defense against development of 
thrombosis (45,131) and is closely linked to inflammation.  Tissue plasminogen 
activator (t-PA) has a major role in activating the fibrinolytic system and initiating 
the release of plasmin, which is responsible for fibrin clot degradation (135).  
However, fibrinolytic activity is impaired by plasminogen activator inhibitor-1 
(PAI-1), the most important inhibitor of plasma fibrinolytic activity (126).  Thus, 
fibrinogen, t-PA, and PAI-1 are perceived as independent risk markers and 
prognostic indicators of cardiovascular disease (11,111,126,135).   
Inflammation (6,21,22,69,130) and fibrinolysis (1,36,135) are suggested 
mechanistic links between cardiovascular disease (CVD) and aging (24).  
However, previous examinations of age-related changes in inflammation and 
fibrinolysis often included questionable “healthy” populations (48) that presented 
with confounding conditions such as hypertension (27), hypercholesterolemia 
(51), diabetes (37), metabolic syndrome (4,28), and smoking (37).  Unfavorable 
changes related to inflammation and fibrinolysis are also associated with obesity, 
defined as a body mass index [BMI] of greater than 30.0 kg/m2 (40), and physical 
inactivity (69,135).  Whole body adiposity and visceral adiposity, in particular, 
are suspected regulators of CRP, coagulation, and fibrinolysis (149,150), and are 
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associated with an increase in inflammation and a decrease in fibrinolysis (34).  
Conversely, inflammation and fibrinolysis are improved with frequent bouts of 
physical activity by means of producing a subsequent decrease in blood 
concentrations of CRP, fibrinogen, and PAI-1, and an increase in blood 
concentration of t-PA (69,72,79).   
  Since body composition and physical activity levels change with age (24), 
these factors must be considered when examining the independent role of age on 
inflammation and fibrinolysis.  Because of the inclusion of subjects with both 
conditions, previous epidemiologic studies have been inconclusive in identifying 
causative factors of age-related elevations of inflammatory and fibrinolytic 
markers.  Therefore, the primary aim of this study was to determine if age was 
related to increased blood levels of inflammatory and fibrinolytic markers, 
independent of body composition and physical activity status. 
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Purposes of the Study 
 
 The purpose of this study was to determine whether: 
1. Age is related to blood concentrations of CRP, fibrinogen, t-PA, and PAI-
1. 
2. Whole body and trunk fat mass are related to blood levels of CRP, 
fibrinogen, t-PA, and PAI-1. 
3. Ambulatory physical activity is related to blood levels of CRP, fibrinogen, 
t-PA, and PAI-1. 
4. The affect of age persists after controlling for ambulatory physical activity 
and fatness. 
 
 
Research Questions 
 
 Research questions for this study include: 
 
1. Are the concentrations of CRP, fibrinogen, t-PA, and PAI-1 in the blood 
related to age? 
2. Is there a relationship between whole body and trunk fat mass and the 
concentration of CRP, fibrinogen, t-PA, and PAI-1 in the blood? 
3. Is there a relationship between the amount of ambulatory physical activity 
and the concentration of CRP, fibrinogen, t-PA, and PAI-1 in the blood? 
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4. Are the concentration of CRP, fibrinogen, t-PA, and PAI-1 in the blood 
related to age independent of whole body fatness, abdominal fatness, and 
ambulatory physical activity? 
 
Research Hypotheses 
 
 Research hypotheses for this study include: 
 
1. The concentration of CRP, fibrinogen, t-PA, and PAI-1 will change with 
increasing age. 
2. Whole body and abdominal adiposity will be positively related to blood 
concentrations of the CRP, fibrinogen, and PAI-1 and negatively related to 
blood concentrations of t-PA. 
3.  Ambulatory physical activity levels will be negatively related to blood 
concentrations of CRP, fibrinogen, and PAI-1 and positively related to 
blood concentrations of t-PA. 
4. After adjusting for whole body fat mass and ambulatory physical activity, 
blood levels of CRP, fibrinogen, t-PA, and PAI-1 will not be related to 
age. 
 
 
Significance of the study: 
 Providing evidence that aging is linked with inflammation and fibrinolysis 
is of high importance, as it may provide an explanation of the causes of age-
related disease.  There are several reports that increasing age is associated with 
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unfavorable changes in inflammation (5,21,22,69,130) and fibrinolysis (34,36).  
Inflammation and fibrinolysis have also been associated with many clinical 
conditions (27,100,125,150), as well as with levels of body fat (39,49,132,150) 
and physical activity (103,145).  The increasing prevalence of clinical conditions 
and unfavorable changes in body composition (i.e., decreased skeletal muscle 
mass and increased total body fat) occurring with age (55,98) could explain 
previous reports of age-related changes in inflammatory and fibrinolytic activity.  
Thus, controlling for these confounding factors, as was done in this investigation, 
helps clarify that levels of inflammation and fibrinolysis are unrelated to age and, 
further, underscore the importance of maintaining higher levels of physical 
activity and lower levels of body fat mass to protect cardiovascular health. 
 
Delimitations 
 Delimitations for this study included: 
1. Participants were community dwelling males and females between the 
ages of 18 – 80 years of age. 
2. Adults with physical disabilities that limited ambulatory movement were 
excluded from the study. 
3. The participation criteria for this study were strict to exclude confounding 
conditions of inflammation and fibrinolysis (i.e., existing diseases, 
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cardiovascular risk factors, bone or joint disorders, respiratory disease, 
chronic or acute infections, etc).   
4. Pregnant women were not allowed to participate. 
5. All subjects were from the greater Oklahoma City, OK metropolitan area. 
 
Limitations 
 Limitations for this study included: 
1. This study used a cross-sectional design; therefore, causal relationships 
can not be determined. 
2. The participants in this study were volunteers and, thus, potentially were 
not representative of the general population. 
3. The StepActivity Monitor is not waterproof; therefore, water activities 
could not be assessed. 
4. The StepActivity Monitor was worn on the ankle; therefore, upper body 
activity could not be quantified independent of overall body movement. 
5. The dietary intake of our subjects was not monitored. 
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Assumptions 
 
 Assumptions for this study included that subjects: 
 
1. Wore the Step Activity Monitor correctly throughout the entire time 
between visits. 
2. Were in a fasted state for the blood draw and for the body composition 
assessment. 
3.  Honestly reported their medical history, age, and race. 
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Operational Definitions 
 
Inflammation - a condition of a chronic, low-grade response instead of the 
classical form  used to describe an acute bout of redness and 
swelling resulting from injury or infection, and is often referred to 
as “microinflammation” (130).   
Fibrinolysis - a cascade of enzymatic reactions designed to breakdown fibrin clot 
formation; our body’s natural defense against thrombosis (45). 
Atherosclerosis - a build-up of fatty substances, cholesterol, calcium or fibrin on 
the inner walls of large and medium-sized arteries (114). 
Hypertension - a blood pressure that is consistently higher than normal (systolic 
pressure ≥ 140 mmHg and a diastolic pressure ≥ 90mmHg) (125).   
Hypercholesterolemia - Above normal serum levels of total cholesterol (> 200 
mg/dL) (46).   
Dyslipidemia - blood levels of low-density lipoproteins, high-density lipoproteins, 
and triglycerides that are outside of the “normal” ranges; (LDL 
≥190 mg/dL; HDL < 40 mg/dL for males and < 50 mg/dL for 
females; Triglycerides ≥ 200 mg/dL) (46). 
Abdominal obesity - a classification for a waist circumference greater than 102 
centimeters in males and greater than 88 centimeters in females 
(46). 
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Body-mass index (BMI) - an index used to assess weight relative to height, and is 
calculated by dividing body weight in kilograms by the square of 
the height in meters (BMI = kg/m2) (46).   
Obesity - defined as BMI ≥ 30.0 kg/m2 denoting an excessive accumulation of fat 
on the body (40). 
Physical activity - any bodily movement produced by skeletal muscles resulting in 
energy expenditure (46).   
Percent body fat (%BF) – the relative percentage of total body weight that is fat-
mass, derived by dividing fat mass by total body mass and 
multiplied by 100 (34).   
Metabolic Syndrome – a condition defined as having at least three of five risk 
factors such as abdominal obesity (waist circumference ≥ 102 cm 
or 40 inches in males, ≥ 88 cm or 36 inches in females), 
dyslipidemia (Triglycerides ≥ 150 mg/dL; high-density lipoprotein 
cholesterol < 40 mg/dL in males and < 50 mg/dL in females), 
raised blood pressure (systolic pressure ≥ 130 mmHg and a 
diastolic of ≥ 85 mmHg), and insulin resistance (fasting glucose ≥ 
110 mg/dL) (46).  
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 CHAPTER TWO 
REVIEW OF LITERATURE 
 
Introduction 
 Cardiovascular disease has been and remains the leading cause of death in the 
United States over the last century and is responsible for nearly 700,000 deaths in the 
U.S. a year (6).  The most recent data show that there are approximately 71.3 million 
known cases of all cardiovascular diseases in the United States (147), with direct 
medical costs tallying approximately $41.2 billion (141).  The predicted overall 
health care expenditures related to cardiovascular disease in 2006 is $403.1 billion, 
which underscores the prevalence and socioeconomic impact on our society (147).   
 Epidemiological data shows that more than 70 percent of all cardiovascular 
disease cases are related to atherosclerosis (141), a build-up of fatty substances, 
cholesterol, calcium or fibrin on the inner walls of large and medium-sized arteries.   
In clinical practice, the term atherosclerosis is often used interchangeably with 
cardiovascular disease.  Several clinical conditions have been recognized as 
traditional risk factors for cardiovascular disease including hypertension (51), 
hypercholesterolemia (27), diabetes (37), obesity (defined as a body mass index 
[BMI] of greater than 30.0 kg/m2) (64), physical inactivity (96) and cigarette 
smoking (26).  Additionally, aging is recognized as an independent risk factor for 
cardiovascular disease (5,21,22,69,130).  Still, numerous elderly patients present 
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with cardiovascular disease even though no co-existing risk factors (25) exist, 
implying that another mechanism could facilitate the development of atherosclerosis.  
 Chronic-low grade inflammation is now suggested as an important 
underlying component in the initial pathology of vascular disease, as it precipitates 
the breakdown of the inner walls of blood vessels (43,114,130).  The fibrinolytic 
system is closely linked to inflammation and is directly involved in coagulation 
processes (45).  Both of these processes have been associated with the development 
and risks of atherosclerosis (9,21).  Is this a mechanistic link between age and 
cardiovascular disease?  This chapter will further review the relations among age, 
inflammation, and fibrinolysis, as well as other influences on these processes. 
 
Vascular Inflammation 
 Over the last decade, evidence has been presented that suggest inflammation 
is an important underlying component in the initial development and progression of 
atherosclerosis (43,114,130).  Traditionally, inflammation has been defined as a local 
response to cellular injury that is marked by capillary dilatation, leukocyte 
infiltration, redness, heat, and pain, serving as a mechanism initiating the elimination 
of noxious agents and damaged tissue.  Inflammation has since been considered to be 
a composite of many different activities brought into action in response to an 
environmental challenge, not a single process (130).  Thus, in this context, the word 
inflammation implies a condition of a chronic, low-grade response instead of the 
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classical form used to describe an acute bout of redness and swelling resulting from 
injury or infection, and is often referred to as “microinflammation.” (130)   
 Recent research has illustrated the inflammatory component in the pathology 
of cardiovascular disease, as well as identified conditions that induce chronic, low-
grade inflammation (97).  There also is a systemic response that accompanies 
inflammation and is known as the acute-phase response.  This response stimulates 
the production of many hepatocyte-derived acute-phase proteins (22).  The most 
popular, C-reactive protein (CRP), is considered to be the “golden marker” for 
chronic, low-grade inflammation (97).  
 The production and activation of CRP by hepatocytes has long been 
considered to be solely  a response to elevated levels of inflammatory cytokines such 
as tumor necrosis factor- alpha and interleukin-6 (79,97), but more recently has been 
shown to play a role in promoting inflammatory processes (48,95).  Specifically, this 
acute phase protein has been localized in atherosclerotic plaques and has 
demonstrated an increased expression in atherosclerotic arterial tissue (24,79), which 
led to speculation of a pro-inflammatory role of CRP.    
 Circulating CRP has demonstrated detrimental affects on endothelial cells by 
increasing adhesion molecule expression on the cell surface (79), impairing 
vasoreactivity by decreasing endothelial nitric oxide expression (18), and up-
regulating the expression of angiotensin receptors in vascular smooth muscle (86).  
CRP is also known to facilitate monocyte and macrophage infiltration into 
endothelial tissue (79).   Collectively, these actions are trademark characteristics of 
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inflammation that, ultimately, result in an unresponsive vessel (i.e., diminished 
arterial elasticity or reduced vascular reactivity), a classical feature of early 
atherosclerotic development (137).  Furthermore, it has been shown that individuals 
in the highest quartile of CRP levels have a relative risk of future cardiovascular 
related events that is three times greater than those in the lowest quartile (112).  This 
potentially explains the well-documented correlations between CRP and incidence of 
atherosclerosis or acute coronary syndrome (12,97,101,111,130), and further 
supports the identification of CRP as an independent risk factor for cardiovascular 
disease.   
 
Inflammation and Aging 
 Aging has consistently been associated with increases in inflammation 
(8,9,23,44,68,115).  Illustrating a link between the two processes is of high 
importance, as it may provide an explanation of the causes, or reflections, of age-
related disease.  Such findings would validate the use of these blood markers as an 
indicator of disease in clinical practice.  Previous studies have shed light on this 
relation, but the design of these examinations (i.e., failure to control for confounding 
physical characteristics) leaves the relation between age and inflammation unclear.  
 The case of age-related changes in acute inflammatory responses has been 
well illustrated with in vitro studies using human endotoxin challenge models.  For 
instance, Krabbe et al. (2001) used a human endotoxin challenge model, in which a 
wall constituent of Escherichia coli, a gram-negative batcteria, was injected 
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intravenously to induce an inflammatory state (68) to identify age-related differences 
in inflammatory response.  While older individuals showed quicker and more 
prolonged inflammatory responses than younger individuals, there was no difference 
in peak inflammation status between the two groups.  In 1999, Bruunsgaard et al. 
used the same type of in vitro stimulation in a large, population-based study (23).  
After the endotoxin infusion, the 80 year old adults showed a greater decrease in 
inflammatory response, represented by tumor necrosis factor – alpha (TNF-α), 
interleukin-1Beta (IL-1β), and interleukin-6 (IL-6) than the 18 to 30 year old adults.  
Further observation showed that the older females, while having lower inflammatory 
responses than the young males, did not show any difference from the young 
females.  These findings actually suggest that there is a decline in age-related 
inflammatory cytokine production and that estrogen produces a suppressive effect on 
inflammation (23).   
 In earlier studies, increased age has been associated with higher levels of 
inflammatory cytokines than in younger adults (19,110).  Specifically, one study (19) 
showed that the concentrations of TNF-α and IL-1β were significantly increased in 
older subjects.  Ironically, the levels of monocytes were unchanged, which suggests 
that immune responses can actually be enhanced with age.  The same increase in IL-
1β production with age was shown by Riancho et al. (1994); however, no age-related 
changes occurred in TNF-α production (110).   
 The conflicting results found in the acute inflammatory response 
investigations are sustained when examining the chronic elevations of circulating 
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markers of inflammation in aging populations.   Many studies conclude that aging is 
associated with increased plasma levels of CRP, TNF-α, and IL-6 (9,22,23).  
However, there are studies that do not support these findings (115).    
 In 1996, Ballou et al. studied a group of older and younger adults who were 
apparently healthy (9).  While this study carefully excluded individuals with 
disorders that could affect CRP levels, they failed to take into account blood 
pressure, cholesterol levels (or pertaining medications), physical activity levels, or 
body composition.  Their findings showed that elderly people  had a significantly 
higher level of CRP (median = 3.0 µg/ml) than a younger group of people (median = 
0.9 µg/ml, p < 0.003) (9).  Within the older group (n = 131), ranging 65-94 years in 
age, there was no significant correlation between age and CRP levels or other acute-
phase proteins (i.e., serum-amyloid A) (9).  These findings weakened the claim that 
age is associated with inflammation.   
 In another cross-sectional study with a larger sample (n = 1327), Ferrucci et 
al. found that inflammation increased with age (48).  To date, this is one of the 
largest age ranges (20 to 102 years) examined.  CRP and IL-6 were significantly 
higher in the age group 65 years of age and older in both males and females even 
after adjusting for the existing clinical conditions.  These conditions included:  
presence of hypertension, history of coronary artery disease or stroke, chronic heart 
failure, diabetes, cancer, and smokers.  However, the sample also included subjects 
of varying body size and physical activity status.  The failure to control for such 
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variances precluded the researchers from confidently concluding that there were age-
association changes in inflammatory status.   
 Changes in circulating inflammatory marker levels have also been examined 
in large population based studies (8,44,115).  In the Framingham Heart study, 711 
elderly individuals did show higher production of IL-6 and IL-1 receptor antagonists 
as compared to a younger control group.  However, no differences in circulating 
TNF-α and IL-1β were found between the two age groups.  Unfortunately, the 
control group only had 21 subjects, which could have biased the conclusions.  
Another study examined subjects enrolled in the SENIEUR protocol, which 
attempted to separate the influence of morbidity and frailty from the physiologic 
process of aging (44).  A secondary analysis found that adults from 69 to 80 years of 
age had higher plasma levels of TNF and IL-6 compared to young controls (22). 
 The studies showing a positive relation between age and inflammation 
support the notion that low-grade inflammatory activity in older individuals is 
independent of co-existing medical disorders.  However, we have yet to clearly 
define the existence of a primary, age-associated dysregulation of inflammatory 
cytokine production.  The findings from some of these studies could have been 
explained by residual confounding factors due to the high prevalence of 
inflammatory, non-cardiovascular conditions in the older populations.  Furthermore, 
there may be age-cohort effects on the levels of inflammatory markers that could not 
be detected in these cross-sectional studies.  Future research focusing on the changes 
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in inflammation occurring with advancing age is necessary to better define this 
relation.  
 
Inflammation and Obesity 
 Obesity has long been associated with an increased risk of developing 
numerous diseases, such as hypertension, dyslipidemia, diabetes, and atherosclerosis 
(60,145).  Several recent studies have also shown an associated between obesity and 
generalized, low-grade inflammation (29,86).  More recently, research shows that 
adipocytes can produce CRP, TNF-α and IL-6, which explains the association 
between obesity and inflammatory activity (34,68,132).  A previous report claims 
that 25 to 30% of circulating IL-6 may be derived from fat (87).  Thus, the age-
associated increase in body fat, especially abdominal adiposity, (55,98) may be an 
important source for increased circulating levels of inflammatory markers in the 
older populations (63).  The remainder of this section will highlight several studies 
addressing the link between obesity and inflammation. 
The primary basis of the suggested causal role obesity has on inflammation is 
supported by many studies showing an increase in circulating inflammatory markers 
in obesity (39,49,132,150).  For example, Yudkin et al. (1999) found a close 
relationship of circulating CRP, TNF-α, and IL-6 concentrations with anthropometric 
measures of obesity in healthy subjects (150).  However, participants were not 
excluded for smoking, hypertension, or hyperlipidemia, and the sample consisted 
largely of overweight individuals.  Specifically, this study compared measures of 
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body composition to levels of CRP, TNF-α, and IL-6 in 107 individuals from 40 to 
75 years of age.  The initial analysis showed that all markers of inflammation were 
significantly related to BMI and waist-to-hip ratio.  When divided into groups of 
“low CRP” (<1.35 µg/mL) and “high CRP” (≥ 1.35 µg/mL), the high CRP group 
unsurprisingly presented significantly higher values of BMI and waist-to-hip ratio.  
This provided an important early observation to stimulate further investigation into 
the link between adiposity and inflammation. 
In another study, markers of inflammation were compared in an obese group 
of pre-menopausal women (n = 56) and a group of age-matched, normal weight 
controls (n = 40) (151).  In the initial baseline assessments, all subjects were 
sedentary with no history of participating in weight-loss related diet programs in the 
previous six months.  The obese group demonstrated significantly higher levels of 
TNF-α, IL-6, and adhesion molecules (ICAM-1 and VCAM-1).  Additionally, the 
concentrations of TNF-α and IL-6 significantly correlated to anthropometric 
measures of “visceral” obesity, represented by waist-to-hip ratio measures (r = 0.55 
and r = 0.45, respectively).  After a baseline visit, the entire obese group participated 
in a 12 month multidisciplinary program of weight reduction, which included diet, 
exercise, and behavioral counseling.  All of the women lost at least 10% of their 
original weight (9.8 ± 1.5 Kg) and, in turn, reduced the circulating blood levels of 
TNF-α and IL-6 (p < 0.01) from baseline to post-intervention.  Regardless of a causal 
origin, this study clearly shows that obesity is related to increases in level of markers 
of inflammation.  While it is also possible that an improved diet regimen or exercise 
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could be, at least partially, responsible for the results of this study, there is a strong 
suggestion that weight loss could be a safe method of reducing inflammatory 
activity. 
Piche et al. (2005) studied the association of obesity and fat distribution on 
inflammation in a group of 112 post-menopausal women (100).  This sample was 
“healthy,” defined as not being clinically treated for heart disease, diabetes, 
endocrine disorders, or additional cardiovascular risk factors.  However, the sample 
still included (and statistically adjusted for) individuals that had a history of 
smoking, hypertension, and dyslipidemia.  CRP concentrations were significantly 
correlated with BMI (r = 0.60) and waist circumference (r = 0.61).  Additionally, IL-
6 levels were related to BMI (r = 0.49) and waist circumference (r = 0.56), while 
TNF-α levels were not.  A more in-depth examination of visceral adiposity, using 
computed tomography, showed that visceral adiposity was also correlated with CRP 
(r = 0.55) and IL-6 (r = 0.49).  As a side note, the total sample was separated into 
three groups: “low CRP concentration” (< 1.0 mg/L), “normal CRP concentration” 
(1.0 – 3.0 mg/L), and “high CRP concentration” (>3.0 mg/L).  There were no group 
differences in age (p > 0.05), but all of the body composition measures were 
significantly different among the groups of differing CRP concentrations.  Once 
again, this study found elevated levels of inflammatory activity in those who were 
obese, while also establishing the importance of the site of fat distribution (i.e., 
visceral adiposity) on mediating inflammation.   
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Another study examined BMI, waist circumference and CRP concentrations 
in a population of persons older than 65 years of age (n = 1,270) (121).  As expected 
in a sample of older people this size, there were a number of individuals who 
presented with clinical conditions including heart disease, chronic heart failure, 
history of stroke, and diabetes.  In general, the individuals presenting with global 
obesity (defined as a BMI ≥ 30.0 kg/m2) demonstrated higher levels of CRP 
concentrations than the non-obese individuals.  The subjects considered to have 
central obesity, defined as being in the upper sex-specific tertile of waist 
circumference (121), had an even higher concentration of CRP than subjects 
classified as non-obese or obese without central distribution of fat.  The group of 
subjects presenting with global and central obesity yielded the highest CRP 
concentrations, suggesting an additive affect of the two conditions on inflammation.   
In further examination, Schrager et al. (2007) found that individuals with 
global obesity had higher concentrations of TNF-α than those with central adiposity 
(121).  The highest concentrations of TNF- α were found, however, in the group 
presenting with both, global and central obesity.  In contrast, IL-6 concentrations 
were highest in the central obesity group, while those with the lowest concentrations 
of IL-6 were in the global obesity group.  The presence of global and central obesity 
did, however, appear to have an additive affect on cytokine concentration that was 
similar to that shown with CRP.  Even with the slight conflict in results between 
inflammation and fat distribution, this study continues to claim that overall obesity is 
related to inflammation.   
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Overall, the studies showing a link between obesity and inflammation are 
consistent, regardless of other potentially confounding clinical conditions.  With 
further evidence that adipose tissue secretes several inflammatory proteins activity 
(34,68), it is probable that excessive amounts of fat are a major source of 
inflammation in many populations (132).  This body of research suggests that the 
changes in body composition that normally occur with age (i.e., decreased skeletal 
muscle mass and increased total body fat) (55,98) could explain some of the 
aforementioned associations between age and inflammation.  In any case, the 
inflammatory response stemming from increasing whole body and, even more 
specific, abdominal adiposity has justified the classification of obesity as an 
independent risk factor of cardiovascular disease.  
 
Inflammation and Physical Activity 
Increasing physical activity level is accepted as a means to decrease risk of 
many health problems, especially cardiovascular disease (72,140).  Additionally, it is 
well documented that increasing amounts of physical activity can result in a decrease 
in the amount of adipose tissue (55,98).  Because of the common connection between 
physical inactivity and inflammation as risk factors for cardiovascular disease, it is a 
logical next step for research to examine the influence of physical activity level on 
inflammatory activity.  
Generally, studies show that more frequent bouts of activity lower blood 
levels of inflammatory and fibrinolytic markers (96,135).  For instance, one study 
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showed that individuals with higher levels of interview based, self-reported physical 
activity had lower concentrations of CRP and IL-6 (109).  Specifically, this study 
examined community-dwelling subjects enrolled in the MacArthur study.  When the 
group was divided into tertiles by amounts of activity, the most active tertile had 
concentrations of CRP and IL-6 that were about 30% lower than the other two-thirds 
of the sample.  Furthermore, individuals incorporating higher amounts of house or 
yard work activities had an additional protective effect beyond that of recreational 
activity on CRP levels, but not IL-6 levels.  These findings are greater than a 
previous report of the group in the top quartile of physical activity the 
Cardiovascular Health Study, a large population based study, presented with up to 
19% lower concentrations of CRP (57). 
 Another cross-sectional study examined the association between physical 
activity and markers of inflammation in a cohort of the Health, Aging and Body 
Composition Study (n = 3,075) (30).  Again, the sample was split into three groups 
based upon amounts of activity: No Activity (0 minutes of exercise per week), Low 
Activity (between 0 and 180 minutes of exercise per week), and High Activity (≥ 
180 minutes of exercise per week).  The concentrations of CRP, IL-6 and TNF-α 
were the lowest in the high activity group.  It should be noted that BMI and the 
prevalence of hypertension, cerebrovascular disease, peripheral vascular disease, 
respiratory disease and diabetes mellitus were also significantly lower in this sample.  
Significance in inflammatory marker concentration remained after adjusting for all 
clinical conditions, but the concentrations of CRP and TNF-α were no longer 
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significantly different between activity groups after adjusting for body composition 
measures.  Although there may be an additive affect, these data suggest that body 
composition may have a greater influence on inflammatory status than physical 
activity. 
 In an examination between leisure time physical activity and markers of 
chronic inflammation, Verdaet et al. (2004) found conflicting results with the 
previously discussed studies (138).  This cross-sectional study found that CRP levels 
were not associated with leisure time physical activity in a cohort of the 
BELSTRESS study.  It should be noted that any affect of activity might have been 
lost due to the fact that the sample included many subjects that smoked, were 
diabetic, or had other co-existing conditions.  Leisure time activity was, however, 
negatively associated with BMI, waist to hip ratio, and the lipid profile.  This 
suggests that these conditions may have more of an influence on inflammatory 
activity than the level of leisure time activity.  This study also suggests that the 
intensity of the activity (or exercise) may have a determining role on inflammation. 
   A study by Pischon et al. in 2003 shed light on this particular question.  A 
group of 859 people was separated into five groups depending on activity status 
(102).  This study extends previous findings that CRP and other markers of 
inflammation are lower in men and women that are more active.  As expected, the 
groups with higher activity (in both men and women) showed an inverse relation 
between CRP, IL-6, and TNF-α.  Specific to CRP, the blood concentrations linearly 
declined through each quintile of activity level, which may suggest a dose response 
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exists on the protective effect of activity on inflammation.  Furthermore, the groups 
of greater activity also demonstrated lower BMIs and a lower prevalence of smoking.  
Adjusting for these factors weakened the association between activity levels and 
inflammation.  Again, this implies that the beneficial association between physical 
activity and inflammation is partially due to less body fat in subjects with higher 
levels of physical activity. 
 Overall, there is a general notion that physical activity and exercise is 
inversely related to chronic levels of inflammatory markers (30,57,102,105).  There 
is a re-occurring observation among all of these studies that allege the link between 
physical activity and inflammation may be mediated by the paralleling changes in 
body composition.  Regardless, these preliminary claims further evidence that 
increasing physical activity can decrease cardiovascular disease risk.  Continued 
research in this area, which is gaining in popularity, will provide the necessary 
clarity to define the relation between physical activity and inflammation. 
 
Inflammation and other clinical conditions 
 Numerous clinical conditions (or co-morbidities) are showing an instigative 
role for inflammation.  While it is traditional and logical to associate inflammation 
with acute infections, many investigators are linking low-grade inflammation with an 
increased prevalence of chronic, asymptomatic infections (22,107).  Interestingly, 
aging is associated with an increased prevalence of many of the same types of 
infections, such as dental infections (85), urinary tract infections (2), and bacterial 
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infections (59,85).  This is a growing concern because bacterial infections can spread 
from the respiratory tract throughout the body via circulating monocytes (113) and, 
in turn, induce systemic immune responses by stimulating inflammatory cytokine 
production (i.e., TNF-α, IL-1β, and IL-6) (108,113). 
 Similarly, a rise in inflammatory markers or fibrinolytic activity can be 
caused by other existing clinical conditions or diseases.  Diabetes (37,90) and 
components of metabolic syndrome (4,28) are shown to elevate inflammatory 
activity.  Additionally, individuals presenting with known cardiovascular disease 
(22), especially atherosclerosis (97), and pulmonary disease (123) consistently have 
higher levels of inflammatory markers than those who are disease free.     
 Hypertension, which has a higher prevalence in older adults, also has been 
linked to chronic, low-grade inflammation (22).  Typically, isolated hypertension is 
defined as a systolic blood pressure ≥ 140 mmHg and a diastolic blood pressure ≥ 90 
mmHg (6th Report).  Yudkin et al. (1999) and Piche, et al. (2005) both found systolic 
and diastolic blood pressure levels were significantly related to markers of 
inflammation (CRP, IL-6, TNF-α) (100,150).  Piche also found that individuals in 
the top two tertiles of CRP concentrations had significantly higher systolic and 
diastolic pressures (100).  While these associations are becoming more popular, it is 
unclear if increased inflammatory activity is a product of sustained high blood 
pressure, or if it instigates hypertension.  Evidence that angiotension II, a potent 
vasoconstrictor, causes monocytes activation would support the idea of an 
inflammatory response to elevated blood pressure (99,120).    
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 Another common clinical condition that is associated with higher levels of 
circulating inflammatory markers is hyperlipidemia (27,51).  In a study by Piche et 
al. (2005), triglycerides levels were positively related (p < 0.05) to levels of CRP (r = 
0.33) and IL-6 (r = 0.32) (100).  As expected, HDL levels were inversely related to 
the same markers of inflammation, demonstrating that higher HDL levels are 
associated with decreased inflammatory activity (100).   These findings parallel 
previous cross-sectional observations linking lipid profiles to inflammation 
(84,111,150). 
 Furthermore, lifestyle characteristics, such as cigarette smoking and alcohol 
intake (139), have been linked to inflammation (27).  In an early study, smokers had 
higher circulating levels of IL-6 compared to their non-smoking counterparts (122)   
Another adjusted analysis showed that CRP and IL-6 (as well as levels of adhesion 
molecules) were independently related to smoking status, which would suggest that 
smoking lead to increases in inflammatory activity (13).  
 There are a couple of additional biological factors that are speculated to 
influence inflammatory activity in humans.  For instance, in 1996, Ballou et al. found 
that black people had slightly higher CRP levels than whites (7.0 vs. 3.0 µg/ml, p = 
0.019) (9).  More so, Native Americans have been shown to have higher levels of 
inflammatory markers than other ethnic groups (84,92).  However, these 
investigations also note that there is a high prevalence of diabetes and metabolic 
syndrome, which could have additive effects on CRP levels.  The genetic role of 
regulating inflammation has recently gained attention in research.  Previous studies 
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have failed to directly link polymorphisms to inflammatory activity (35,142).  There 
are known gene polymorphisms, however, that are related to several diseases, 
including insulin resistance, Alzheimer’s disease, and arthritis, which could 
assuredly increase inflammatory activity (22,31,33).    
 The chronic inflammation resulting from these conditions can explain a 
mechanistic link between the traditional risk factors and atherosclerotic 
development.  Furthermore, the associations between clinical conditions and 
inflammatory, while significant, may only explain a small part of the low-grade 
inflammatory activity (22,23).  Regardless, excluding subjects presenting with these 
characteristics can remove any confounding influence on inflammation in future 
research studies. 
 
Fibrinolysis 
 Fibrinolysis is a cascade of enzymatic reactions, bringing together 
plasminogen and its activators (tissue plasminogen activator, and is designed to 
breakdown fibrin clot formation (45,150).  Specifically, tissue plasminogen activator 
(t-PA) has a major role in activating the fibrinolytic system and initiating the release 
of plasmin, the protein responsible for lysing fibrin clots (135). The essential balance 
in plasma is largely between t-PA and the inhibitor, plasminogen activator inhibitor -
1 (PAI-1) (88).  PAI-1 is the most important inhibitor of plasma fibrinolysis (126).  
An increase of plasma t-PA and PAI-1 are both indicative of an increase in 
fibrinolytic activity (126,135) and can result in a pro-thrombotic state.  When PAI-1 
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concentrations reach a level four or five times greater than the activators, 
haemostatic conditions favor fibrin clot formation (i.e., hypofibrinolysis) (88).   
 Fibrinogen, another acute-phase protein, is often considered as a marker of 
inflammation (11).  However, fibrinogen is more of a determinant of blood viscosity, 
an important factor in blood clot formation (41,42).  In addition to serum 
concentrations of CRP, fibrinogen is not only associated with the risk of developing 
cardiovascular disease, but is also indicative of the severity of existing disease 
(107,111).  Therefore, fibrinogen is perceived as another independent marker of 
cardiovascular disease risk as well as a prognostic indicator (11).   
Clot formation is an essential protector from bleeding, but persistent 
conditions can ultimately lead to thrombosis.  The fibrinolytic system is our body’s 
natural defense against thrombosis.   Thrombosis exacerbates the risk of a 
catastrophic acute coronary episode in the presence atherosclerotic plaques, 
especially if the plaques rupture.  The increase in fibrinolytic activity is capable of 
independently predicting catastrophic cardiovascular disease related events (52).  
Thus, t-PA and PAI-1 are recently being considered additional, independent risk 
markers of cardiovascular disease.  
The role of fibrinolysis in the early development of atherosclerosis is a rather 
new idea.  It is suggested that excessive amounts or fragments of fibrin can be 
deposited in the vessel wall, contributing to the progression of atherosclerotic 
lesions.  Specifically, recent clinical evidence suggests that low fibrinolytic activity 
is a determinant of major CHD events in young and middle-aged men (82).  
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Furthermore, high PAI-1 activity combined with a low plasminogen activator 
capacity were risk factors for re-infarction in young, male survivors of myocardial 
infarction (62).  Another study, also carried out in persons with severe CHD, found 
that tissue plasminogen activator antigen, but not plasminogen activator inhibitor 
activity, was predictive of total mortality during a 7 year follow-up.  Thus, there is 
still a need for clarification of the determinants of coagulation and fibrinolytic 
activity. 
 
Fibrinolysis and Aging 
Age-related changes in coagulation and fibrinolytic factors are speculated to 
be contributors to the increase in risk of thrombotic events in older adults (61,67).  
Increases in fibrinogen and other coagulation factors, without a proportional increase 
in anticoagulant factors, likely contribute to this risk (61). Over the past couple of 
decades, a positive correlation between age and the occurrence of thrombosis has 
been presented (36,148).  Hashimoto et al. presented some of the first evidence of a 
relationship between age and fibrinolytic activities; namely levels of tissue 
plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PA inhibitor) 
activity, and plasminogen activator activity (PA activity). A dramatic increase in 
both t-PA antigen and the plaminogen activator inhibitors was shown in persons with 
increasing age, while t-PA activity decreased with age.  
DeSouza et al. (1998) also examined the age differences in coagulations and 
fibrinolytic factors in pre- and post-menopausal women, as well as identifying the 
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impact of habitual exercise on these hemostatic factors in the two age groups (36).  
To do so, they set up four groups:  (1) pre-menopausal sedentary, (2) pre-menopausal 
active, (3) post-menopausal sedentary, and (4) post-menopausal active.  They 
measured resting levels of plasma fibrinogen, tissue-type plasminogen activator (t-
PA) antigen and activity, and plasminogen activator inhibitor-1 (PAI-1) activity as 
indicators of coagulation and fibrinolytic factors.  The post-menopausal had 
significantly higher (p < 0.05) levels of fibrinogen, t-PA antigen, and PAI-1 lower t-
PA activity than the pre-menopausal women, indicating that fibrinolysis is impaired 
with age.  Furthermore, the active post-menopausal women demonstrated lower (p < 
0.01) plasma fibrinogen, t-PA antigen, and PAI-1 activity and higher (p < 0.01) t-PA 
activity levels than the sedentary post-menopausal women (36).  Even more 
importantly, the fibrinolytic profile of Post-PA did not differ from that of the active 
premenopausal women.  This suggests that the adverse age-associated differences, 
however great they may be, in plasma fibrinogen concentrations and the endogenous 
fibrinolytic system in sedentary healthy women are either attenuated or absent in 
highly physically active women.   
Changes in the endothelium, including early development of atherosclerotic 
plaques, have been proposed as potential contributors to the increase in thrombotic 
cardiovascular disease found in the elderly (148).  The capacity of the vascular 
endothelium locally to release t-PA is critical for effective endogenous fibrinolysis. 
Using both cross-sectional and intervention approaches, Smith et al determined the 
influence of ageing and regular aerobic exercise on the net release of t-PA across the 
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human forearm in vivo (127). They studied the endothelial release rates of t-PA in 62 
healthy men aged 22-35 or 50-75 years of age who were either sedentary or 
endurance exercise-trained.   Similar to DeSouza’s findings (36), net endothelial t-
PA release was significantly blunted (approximately 35% less, p < 0.05) with age in 
the sedentary men, while no age-related declines in net release of t-PA antigen were 
found in the endurance-trained men. Again, these results illustrate that endothelial t-
PA release declines with age in sedentary men, but the decline could be prevented, or 
even reversed with regular aerobic exercise.  Perhaps the tendency of decreased PA 
activity with increasing age may be related to the high incidence of thrombosis in 
older persons.  The influence of physical activity and exercise on fibrinolysis will be 
later discussed in this chapter.   
In 2005, Yamamoto et al. examined if gene expression of PAI-1, as the 
principal inhibitor of fibrinolysis, varied across increasing age (148).  The expression 
of PAI-1 is not only elevated in the elderly but also significantly induced in a variety 
of pathologies associated with the process of aging, such as obesity, insulin 
resistance, and vascular sclerosis.  Furthermore, the gene expression of PAI-1 was 
found to be positively regulated by several cytokines and hormones.  These included 
tumor necrosis factor-alpha, a marker of systemic inflammation, and angiotensin II, a 
mediator of vasoconstriction.  This raises suspicion that impaired fibrinolysis may 
result from an inflammatory interaction (148). Additionally, it could explain the 
heightened risk for thrombotic cardiovascular disease in obesity with aging, as 
adipose is a known source of inflammatory cytokines.  None the less, future studies 
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on the genetic regulators of aging-associated PAI-1 induction will be necessary to 
define the basis for cardiovascular aging in relation to thrombosis. 
 Overall, these studies show that increasing age is consistently associated with 
a decrease in fibrinolytic activity (36,61,148).  While this could be a primary affect 
of aging, the data showing that increasing physical activity levels negate this affect 
and introduce new factors that dilute the clarity of this relation (36,127).  Is this an 
age effect?  Or is this more of a result of age-related declines in physical activity 
patterns?  Other conditions that can affect fibrinolysis, and coincidentally change 
with age, will be discussed in the following sections.  But regardless of why or how, 
further studies will be warranted to define the mechanisms for thrombosis in the 
elderly as the population ages. 
 
Fibrinolysis and Obesity 
 Obesity has repeatedly been shown to be associated with PAI-1, the major 
fibrinolysis inhibitor (78,81,134).  PAI-1 is directly correlated with BMI (133) and 
waist-to-hip ratios, indicating an influence from abdominal fat (134).  More 
specifically, adipocytes have recently been shown to produce and mediators of 
fibrinolysis (126), which explains the link between high levels of fibrinolytic 
markers with excessive adiposity (i.e., high percent body fat) (34).   
In a two-part study, a group of investigators examined a group of 66 
sedentary adults, which included 28 normal-weight, 22 overweight, and 16 obese 
adults (136).  In the first, cross-sectional observation, the amount of t-PA antigen 
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released from endothelial was significantly lower (p < 0.05) in the overweight and 
obese adults, compared to their normal weight peers.  In a bivariate analysis, the total 
amount of t-PA antigen release was inversely related (p < 0.05) to body mass (r = -
0.47), percent fat (r = -0.29), BMI (r = -0.36), and waist circumference (r = -0.28).  
The impaired endothelial t-PA release found in overweight individuals further 
support the notion that impaired fibrinolysis is a consequence of obesity, with 
specific emphasis on abdominal adiposity.   
 Mavri et al. (1999) enrolled 52 obese, pre-menopausal women in a 10-12 
week body weight reductions program, with 19 age-matched lean women as a 
control group (78).   PAI-1 concentrations were measured at the time of entry, one 
week after the start of the program, at time of program completion, and five months 
after program completion.  At the start of the program, PAI-1 activity concentrations 
were positively correlated with BMI (r = 0.35), waist-to-hip ratio (r = 0.30), and an 
equation derived percent body fat (r = 0.43).  At the end of the program, women 
reduced their body weight by 17% and their percent body fat by 13%, while PAI-1 
activity had decreased by 74%.  However, five months after program ended, 16 
women regained over 25% of their original body weight.  As a result, PAI-1 activity 
levels significantly increased, paralleling the increase in BMI.  Thus, this study 
suggests that the elevated PAI-1 levels seen in obesity are closely linked to the 
amount of adipose tissue stored (78). 
 For three months, 55 subjects participated in a weight loss program using 
meal replacements or a structured eating plan (29).  At the end of the study, mean 
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weight loss was 6.3 ± 3.7 kg with no differences between diet groups.  As a whole, 
PAI-1 concentration significantly decreased from baseline to after weight loss (70.84 
± 30.91 ng/ml vs. 55.55 ± 31.64 ng/ml, respectively, p < 0.001).  Furthermore, t-PA 
levels dropped by 7% (p < 0.05) from baseline.  As a side note, individuals 
presenting with CRP concentrations higher than 10 mg/L at baseline showed 
significant reductions after the three month diet intervention (3.65 ± 2.15 mg /L vs. 
3.01 ± 2.19 mg/L, p < 0.01).  This supports the previous findings showing that 
weight loss intervention leads to a reduction in fibrinolytic activity (78). 
Bouchard et al examined if there were polymorphism variations the PAI-1 
gene related to body fat and abdominal fat mass (20).  In women, BMI and body fat 
mass was associated with the PAI-1-675 4G/5G, while abdominal visceral fat mass 
was related to the same polymorphism and the c43G>A variant within the exon 1.  
Furthermore, carriers of the -675 5G and the 43A allele had nearly 50% more 
visceral fat (assessed by computed tomography) compared to the -675 4G allele.  
None of these associations were found in the men.  These findings support previous 
claims that PAI-1 polymorphisms may be associated with BMI (65).  However, this 
is the first study to observe an association between the PAI-1-675 polymorphisms 
and measures of whole body and abdominal fat mass.  This implies that the 
association between PAI-1 activity and fat distribution may be influenced by more 
than lifestyle characteristics, particularly in women. 
 There is overwhelming evidence showing that obesity is associated with 
impaired fibrinolysis (78,81,134).  With specific emphasis on abdominal adiposity, 
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these studies provide a mechanism that bridges obesity with cardiovascular disease 
(136).  As previously mentioned, the changes in body composition occurring with 
age (i.e., decreased skeletal muscle mass and increased total body fat) (55,98) could 
possibly explain prior observations of a relation between age and fibrinolysis.  At 
any rate, the rationale for classifying obesity as an independent risk factor for 
cardiovascular disease continues to grow with this evidence that decrease in 
fibrinolytic activity decreases with increasing whole body and, even more specific, 
abdominal adiposity. 
 
Fibrinolysis and Physical Activity 
 Over the last few decades, it has become quite clear that regular aerobic 
exercise is associated with a reduction in cardiovascular events in overweight and 
obese adults, independent of weight changes (14,136).  As a contributing 
mechanism, the affects of physical conditioning on fibrinolysis were examined more 
closely (7,32,47).  By comparing 60 healthy men in three physical fitness categories 
(sedentary, joggers, and marathoners), Ferguson et al. discovered that fibrinolytic 
activity increased with exercise early on (47).  More recently, physical activity is 
consistently understood to be inversely correlated with blood levels of fibrinolytic 
markers (96,135), a suggested protective mechanism of physical activity against 
cardiovascular disease.  The general notion is that more frequent bouts of activity 
can lower blood levels of fibrinolytic activity.   
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 Acute fibrinolytic responses to exercise are also being examined and are of 
high clinical relevance, as numerous catastrophic events occur from an occlusive 
thrombus (58).  With previous evidence of an increased potential for blood 
coagulation during physical exertion (7,32), there is an urgency to learn if a body can 
counter by increasing fibrinolytic activity (144,145).  Womack et al. examined the 
acute changes in fibrinolytic activity occurring with exercise (146).  Specifically, 15 
healthy males performed three different cycle ergometer tests:  (1) a VO2max and 
lactate threshold test, (2) a one hour exercise session over lactate threshold, and (3) a 
one hour exercise session below lactate threshold.  t-PA activity was significantly 
higher immediately following the exercise above lactate threshold, but not in the 
exercise below the lactate threshold.  The concentrations of t-PA antigens were 
significantly higher immediately following both exercise conditions, but were still 
significantly higher in the exercise session above lactate threshold.  PAI-1 activity 
significantly decreased during both exercise conditions; however, the decrease 
occurring in the exercise below lactate threshold only occurred when post-exercise 
values were corrected for plasma volume changes.  All marker concentrations, 
except t-PA antigen levels in the above lactate threshold exercise, returned to 
baseline within the one hour post measurement.  Overall, this study demonstrates 
that intensity is a more important determinant on acute fibrinolytic responses to 
exercise, showing that exercising below the lactate threshold elevates t-PA antigen 
levels but not t-PA activity (146).  Thus, a higher intensity exercise can heighten 
fibrinolytic activity. 
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 In a previously discussed study, Van Guilder et al. enrolled 17 overweight or 
obese individuals (11 males, 6 females) of the total 66 initially examined subjects in 
a three month, home based aerobic exercise training program (136).  During their 
participation, subjects were asked to exercise 5-7 days per week, 40-50 minutes a 
day, at 60-75% of their maximum heart rate.  After the training program was 
completed, there were no changes observed in basal release rates of t-PA or PAI-1 
antigens.  However, t-PA release rates were markedly increased after bradykinin 
infusions, increasing net t-PA antigen amount by nearly 55%.  This evidences that 
there is, indeed, an improved capacity of the endothelium to release t-PA in 
overweight and obese adults.  Because these changes occurred without a paralleled 
shift in body size or composition, there is a much stronger notion that aerobic 
activity may have a primary modulatory effect on endothelial fibrinolytic regulation 
(136).   
 Another report showed that leisure-time physical activity was not an 
independent predictor of fibrinogen (138).  In a sample of 892 male subjects, leisure-
time physical activity (LTPA) was related to a number of cardiovascular risk factors, 
such as BMI (p = 0.01), waist to hip ratio (p < 0.001), and HDL levels (p = 0.003).  
Unadjusted means across the four categories of LTPA (“No LTPA,” “Low LTPA,” 
“Moderate LTPA,” and “High LTPA”) showed a significant inverse relationship 
with CRP (p = 0.02) and fibrinogen (p = 0.02).  However, in a multivariate analysis 
adjusting for BMI, smoking status, presence of diabetes, and alcohol consumption, 
these relationships were no longer significant (p > 0.05).  This indicates that there is 
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no independent association between LTPA and markers of inflammation or 
fibrinolysis and further strengthens the previously discussed claims that intensity has 
a greater influence than duration (146). 
 Exercise interventions have also been shown to have beneficial effects in 
clinical populations, especially those with cardiovascular disease (91,100).  
Killewich et al. (2004), studied 21 patients with peripheral arterial disease (PAD) 
(70).  After completing a six month training program of treadmill exercise three 
times a week, fibrinolytic activity significantly improved, expressed as a 23% 
reduction in PAI-1 activity and a 28% increase in t-PA activity.  No changes were 
noted in a control group of 20 age-matched men presenting with claudication.  
Additionally, it was noted that the greatest improvements in fibrinolytic activity 
occurred in individuals with the lower amounts of fibrinolysis (i.e., highest levels of 
PAI-1 activity).  This adds to the growing body of literature evidencing a beneficial 
effect of exercise on fibrinolysis.  Combined with the other studies of similar 
outcomes, these data suggest that serious consideration should be given to exercise 
interventions as a treatment option in cardiovascular patients.   
 In 2002, Wannamethee et al. examined the relations between physical 
activity and hemostatic variables in a large population based study (140).  In 3810 
adult men, physical activity showed a significant inverse dose response relationship 
with many hemostatic variables, including fibrinogen, t-PA antigen, and CRP.  In 
this case, physical activity was collected by interview with a score assigned and used 
to categorize partcipants into one of six groups:  (1) “No activity,” (2) “Occasional 
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Activity,” (3) “Light Activity,” (4) “Moderate Activity,” (5) “Moderate to Vigorous 
Activity,” and (6) “Vigorous Activity.”  As expected, the diseased men presented 
consistently higher values of these blood markers in every activity group, but the 
inverse relationships were similar between men with and without cardiovascular 
disease.  This supports the notion that the benefit of physical activity on 
cardiovascular disease may be, at least partly, due to the positive effect on 
fibrinolysis (140). 
In the past twenty years, research has illustrated the positive influence of 
regular aerobic exercise in fibrinolysis (14,37,136).  Although more research can 
more clearly define a dose-response effect of exercise, the benefits on cardiovascular 
disease may be, at least partly, due to the positive effect on fibrinolysis (140).  
Moreover, the tendency of decreased PA activity with increasing age may be related 
to the high incidence of thrombosis in older persons. 
 
Fibrinolysis and other clinical conditions 
 There is a well defined association between fibrinolysis and known diseases, 
such as cardiovascular disease (75), diabetes (37), and components of metabolic 
syndrome (4,28,140).  Early development of atherosclerotic plaques has also been 
shown to impair fibrinolytic activity (119).  In 1995, a cross-sectional case-control 
study with 457 pairs of subjects found that t-PA and PAI-1 were higher (p ≤ 0.001) 
in patients above the 90th percentile of intima-media thickness of carotid arteries 
compared to those having a thickness below the 75th percentile of the Atherosclerotic 
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Risk in Communities (ARIC) Study (119).  These findings led to the notion that 
thrombosis and fibrinolysis may play a role at the early stage of the atherosclerotic 
process. 
 Hypertension is an established risk factor for acute coronary events that is 
also being associated with impaired fibrinolysis (25,53,103,128).  In a cross-
sectional investigation, the relations of systolic and diastolic blood pressures (SBP 
and DBP) to levels of plasminogen activator inhibitor antigen, tissue plasminogen 
activator antigen, fibrinogen, were examined in 1193 men and 1459 women of the 
Framingham Offspring Study (103). In both sexes, levels of plasminogen activator 
inhibitor and tissue plasminogen activator antigen were positively related to systolic 
and diastolic blood pressures, even after adjusting for age, body mass index, 
smoking, diabetes, total cholesterol, HDL, triglycerides, alcohol intake, and estrogen 
use in women (p < 0.001).  However, there was no association between systolic and 
diastolic blood pressure in either sex.  These data provides another potential 
mechanism by which hypertension contributes to the pathogenesis of cardiovascular 
disease in hypertensive patients. 
 The negative influences of hypertension on fibrinolysis have been alleviated 
by exercise (36).  Specifically, hypertensive subjects had a 172% increase in t-PA 
activity and a 25% decrease in PAI-1 activity after an acute bout of exercise (36).  
There are pharmacological treatments of hypertension that have an interfering role 
on fibrinolysis as well (103).  As it is known that angiotension II increases PAI-1 
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activity (89,148), angiotension converting enzyme (ACE) inhibitors decrease PAI-1 
levels and increase t-PA levels (103). 
 Numerous reports have also shown a link between impaired fibrinolysis and 
high cholesterol levels, another established risk factor of cardiovascular disease 
(93,105,106).  Puccetti et al. compared individuals with hypercholesterolemia, 
hypertriglyceridemia and low HDL cholesterol levels in 75 males and females (105).  
Hypertriglyceridemia patients were found to have higher PAI-1 serum levels 
compared to hypercholesterolemia and control subjects (p < 0.001).  Impaired 
fibrinolysis in subjects with hypertriglyceridemia or low HDL-cholesterol is 
associated with increased serum levels of PAI-1 whereas enhanced thrombin 
generation was the main finding in hypercholesterolemia.  Such data may suggest the 
opportunity of evaluating several fibrinolytic factors when studied as prognostic 
factors in varying lipid profiles.  Furthermore, Orem et al. showed that, after 
successful lipid lowering therapy, statin use improved global fibrinolytic capacity (p 
= 0.003), increased tissue plasminogen activator levels (p = 0.04) and decreased 
plasminogen activator inhibitor type-1 levels (p = 0.02) in dyslipidemia patients (93).  
Thus, pharmacological treatment may negate the negative effect of 
hypercholesterolemia on the fibrinolytic system.  
 The association between fibrinolysis and cigarette smoking, an established 
risk factor for cardiovascular disease, is less apparent than the relation between 
smoking and inflammation (35,38).  One study showed that non-smokers had 
significantly higher (p < 0.03) levels of t-PA activity than current or former smokers 
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(91).  Another study showed that there were no differences in fibrinogen levels 
between smokers and non-smoker (35).  In contrast, a third investigation found that 
smokers had fibrinogen levels 0.34 g/L higher than non-smokers, showing a 
correlation between number of cigarettes smoked and plasma fibrinogen levels (r = 
0.21, P = 0.006) (38).  Collectively, these studies fail to clarify the association, if 
any, between fibrinolysis and smoking.   
 Another lifestyle factor that can influence fibrinolysis is alcohol 
consumption, showing that regular moderate alcohol intake can reduce coagulation 
and increase fibrinolysis (118,139).  More specifically, Salem et al. found that 
individuals drinking 240 mL of red wine a day, showed increased levels of t-PA 
antigen and PAI-1 antigen, and lower levels of fibrinogen (118).  The greatest benefit 
of alcohol consumption on fibrinolysis occurred in people following a low fat diet.  
Those ingesting diets of high fat content did not have improved fibrinolytic activity.  
Perhaps, this is another mechanism bridging a high fat diet to cardiovascular disease.    
 Impairments in fibrinolysis resulting from these clinical conditions present 
another potential mechanism that links traditional risk factors to the development of 
cardiovascular disease.  Such claims support the notion that thrombosis and 
fibrinolysis may contribute to atherosclerotic development.  However, traditional 
treatments (i.e., pharmaceutical or physical activity interventions) for these 
conditions do show a beneficial affect on fibrinolytic activity (36,93,103).   
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Summary 
 Chronic-low grade inflammation is becoming a well-recognized component 
of vascular disease pathology, as it instigates the breakdown of the inner walls of 
blood vessels (43,114,130).  Components of the fibrinolytic system, more commonly 
associated with the coagulation process, are suggested to not only exacerbate 
existing vessel disease, but also to facilitate atherosclerotic development (45,131).  
As discussed throughout this chapter, much attention has been placed on identifying 
factors that affect inflammation or fibrinolytic activity.   
 In the past several years, the age-related changes occurring with these two 
conditions have been suspected to bridge aging and the increased prevalence of 
cardiovascular disease.  However, paralleling changes in physical and clinical 
characteristics that occur with age (e.g., decreased physical activity levels, increased 
body fat, and an increased prevalence of other clinical conditions) make examining 
age-related changes in inflammation and fibrinolysis difficult.  In fact, the failure to 
exclude, or at least statistically adjust for, these confounding conditions dilute the 
previous claims regarding the association between advancing age and hemostatic 
changes.  Thus, we have yet to clearly define the existence of a primary, age-
associated dysregulation of inflammatory cytokine production and thrombolytic 
degradation systems.  Maybe there is no sole connection between these instigators of 
vascular disease and the unavoidable aging process.  In order to clarify this 
relationship, it is crucial that such factors are considered when examining the age-
related changes in inflammation and fibrinolysis. 
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CHAPTER THREE 
 
METHODOLOGY 
 
 
 
 The primary aim of this study was to examine the independent relationship 
between age and blood levels of inflammatory and fibrinolytic markers.  To 
isolate this relationship, the relationship between additional confounding factors 
(i.e., body composition and physical activity levels) and the concentrations of 
inflammatory and fibrinolytic markers were examined.  The specific procedures 
and methods of this study to evidence these relationships are described in detail 
throughout this chapter. 
 
Study Population 
 Males and females of any race between 18 and 90 years of age were 
recruited for this examination.  The ultimate goal for recruitment into the study 
was set at 80 subjects with equal division among males and females.   
Recruitment of women and minorities into this protocol were a high priority to 
assess inflammatory markers, physical activity, and body composition among 
various demographic groups.  This study was conducted on an outpatient basis, in 
the General Clinical Research Center (GCRC) on the University of Oklahoma 
Health Sciences Center (OUHSC) campus.  The protocol was approved by the 
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GCRC Advisory Committee (Protocol #0103) (Appendix C) and the OUHSC 
Institutional Review Board (#11841) (Appendix D), and was supported by the 
OUHSC GCRC grant (M01-RR-14467) sponsored by the National Center for 
Research Resources from the National Institutes of Health. 
 To participate in this study, the inclusion criteria states that an individual 
must be between 18 and 90 years of age, ambulatory, and living independently at 
home.  Subjects were excluded from the study if they presented with any of the 
following criteria: 
1. Unable to perform physical activity: Non-ambulatory or other neuro-
musculoskeletal limitations. 
2. Non-independent living as determined by Impairments in Activities of Daily 
Living (ADL) and Instrumental Activities of Daily Living (IADL) 
3. History of atherosclerotic cardiovascular diseases (ACVD): 
a. Coronary artery disease (CAD): Angina pectoris, current or history of 
unstable angina, history of myocardial infarction, history of coronary 
angioplasty or stents, history of coronary artery bypass graft, acute 
coronary syndrome 
b. Peripheral arterial disease (PAD): Ankle-brachial index (ABI) = 0.9 or 
less, history of intermittent claudication, history of aorto-femoral or 
any other lower extremity bypass surgery for occlusive PAD, history 
of ischemic gangrene or amputation,  
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c. History of aortic aneurysm (thoracic or abdominal) 
d. History of cerebral vascular disease: History of carotid stent, carotid 
endarterectomy, stroke or transient ischemic attack (TIA) 
e. History of atherosclerotic renal artery disease 
f. History of congestive heart failure (CHF) 
4. Atherosclerotic cardiovascular risk factors (ACVRF): 
a. Having metabolic syndrome, defined as three or more of the 
following:  
i. Abdominal obesity: waist circumference > 40 in (102 cm) in 
men or > 35 in (88 cm) in women 
ii. Blood pressure ≥130/85 mm Hg 
iii. Fasting blood glucose ≥ 110 mg/dL 
iv. Fasting plasma high-density lipoprotein (HDL) cholesterol < 
40 mg/dl (men) or < 50 mg/dL (women) 
v. Fasting plasma triglycerides ≥ 150 mg/dL 
b. Smoking: current or within past 12 months 
5. Pulmonary diseases: chronic obstructive lung disease (COPD), asthma, 
reactive airway disease, bronchitis, pneumonia, pulmonary fibrosis,  
6. Active renal disease 
7. Rheumatologic diseases: Rheumatoid arthritis, systemic lupus erythematosis 
(SLE), scleroderma, or any other autoimmune disease 
 47
8. Endocrine diseases: Diabetes, hypo- or hyper-thyroidism, Cushing’s 
syndrome, Adrenal diseases 
9. Gastro-intestinal disease: Peptic ulcer disease, gastro-esophageal reflux 
disease, inflammatory bowel disease (Crohn’s disease or Ulcerative colitis), 
10. Liver diseases 
11. Active Cancer or active chemo- or radio-therapy 
12. Psychiatric impairments: Cognitive impairment (mini-mental status 
examination score = 23 or less), depression, psychosis, delusions 
13. Substance abuse: Alcohol abuse current or within past 10 days, any other 
substance abuse 
14. Recent vaccination: influenza, pneumovax, or others 
15. Infectious diseases: Common cold or any other acute infection within 14 days 
16. Medications: regular use of non-steroidal anti-inflammatory drugs (NSAIDs) 
17. Surgery within past 3 months 
18. Strenuous physical activity within 48 hours. 
 Prior to enrolling in the study, each subject underwent a brief telephone 
interview to reveal any potential exclusionary conditions.  During this screening 
interview, over 80 individuals were excluded from participation due to regular 
medication use (e.g. anti-hypertensives, anti-inflammatory, cholesterol lowering 
drugs) or pre-existing medical conditions (e.g. known cardiovascular disease, 
arthritis, gastro-intenstinal disorders).  If subjects declined to wear the physical 
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activity monitors, their participation in the study would have concluded at the end 
of the first visit.  Additionally, study participation would have been terminated 
early if the subject declined to participate in any of the remaining tests, or if the 
test administrator believed that it was in the best interest of the subject not to 
participate.  However, all subjects who qualified for participation in the study 
completed all tests. 
 
Recruitment 
Subjects of any race from 18 to 90 years of age were recruited for this 
examination.   The goal for recruitment into the study was set at a minimum of 60 
subjects and a maximum of 80 subjects with equal division among males and 
females.   The subjects were recruited using newspaper advertisements, email 
announcements to OUHSC and OU faculty and staff, and media flyers.  
Recruitment of women and minorities into this protocol was a high priority to 
obtain measures of inflammatory markers, physical activity, vascular function, 
and body composition among various demographic groups.  This study was 
conducted on an outpatient basis, in the General Clinical Research Center 
(GCRC) on the OUHSC campus.  At the end of each visit, the subjects received a 
small meal.  A report and an explanation of the results obtained was prepared for 
and given to all subjects after the tests were completed.   
 
 49
Research Design 
This was a three-visit, cross-sectional study in which the levels of 
inflammatory and fibrinolytic markers were measured via blood samples in 
apparently healthy subjects.  Additionally, tests were administered to assess body 
composition and monitors were provided to assess physical activity.  The 
independent variable of this study is age of the participant.  The dependent 
variables of this study are the blood levels of the inflammatory and fibrinolytic 
markers.  The descriptive characteristics of the subjects were considered as 
potential covariates in the final analysis of the study.   
 
Research Protocol 
During this study, the subject completed three visits within one week, 
illustrated in Figure 1.  During the first visit, the subject completed the informed 
consent (Appendix A) and HIPAA forms (Appendix B).  Each subject also 
completed an initial screening to evaluate his or her health and medical history.  
Additionally, a blood draw was performed to obtain specimens for all blood tests.  
The first visit lasted approximately one hour. 
On the second visit, the subjects completed a physician conducted health 
screening to ensure the subjects were healthy and free on all confounding 
conditions highlighted in the exclusion criteria.  This screening was completed on 
the second visit so the attending physician could examine the blood chemistry 
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reports to identify any underlying exclusionary conditions.  Physical activity 
monitors were given to the subject and they were instructed how to properly wear 
the device.  Additionally, a dual energy X-ray absorptiometry (DEXA) scan was 
performed to assess body composition.  The second visit lasted about one hour.   
 On the third and final visit, the subjects returned the physical activity 
monitor and any tests that were not conducted in the first two visits were 
completed.  For example, if a subject was not fasting on the second visit, the 
testing was completed during the third visit.  This visit could have lasted up to 
about one hour.  
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 Telephone Screen: Brief medical history 
for initial health screen.  
 
-Study Explanation given 
-Preliminary Consent Obtained 
While fasting: 
- Informed Consent, blood pressures, height, 
weight, ankle/ brachial index  
 
- Blood draw for CBC, CMP, blood lipids, 
inflammatory and fibrinolysis. 
While fasting: 
- History and physical examination 
performed by physician. 
 
- DEXA for body composition assessments 
 
- Physical activity monitor issued. 
Initial Screening 
(20 Minutes) 
1st Visit 
(1 hour) 
2nd Visit 
(1  hour) 
IF individual is not excluded 
Figure 1.  Flow Chart of Subject Participation. 
IF individual is not excluded 
3rd Visit 
(30 minutes) 
Non-Fasted:  
- Turn in physical activity monitor and data 
downloaded 
   
- Any incomplete tests from visit 2. 
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Instruments and Measures 
 
Health Screening Measurements 
 Prior to completing any of the tests in this study, preliminary information 
regarding health status was obtained.  This included age, height, weight, blood 
pressure, sex, race, complete blood count (CBC), comprehensive metabolic 
profile (CMP), and blood lipid panels.  In addition, a medical history and a 
physical examination was performed by the GCRC site physician to confirm that 
all participants in the study were free of any conditions in the exclusion criteria.   
 
Physical Characteristics of the Subjects 
 The age and race of the subjects were obtained by self-report.  The age 
was recorded to the nearest year.  The race was recorded as:  Caucasian, Asian, 
African American, American Indian, Hispanic, or Other.  
 Height was measured using a wall-mounted stadiometer (Accustat™ 
Genentech® Inc.; San Francisco, USA).  All subjects were asked to remove their 
shoes and stand up straight against the stadiometer, with their feet flat on the 
floor.  The height was measured as the distance from the floor to the top of the 
head and recorded to the nearest 0.1 cm.  After removing any excess clothing, 
jewelry, and objects from their pockets, the subjects were then weighed by an 
electronic scale (Seca, Vogel & Halke; Germany).  Weight was measured to the 
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nearest 0.1 kg.  Body mass index (BMI) was calculated from the height and 
weight measurements, as follows:  BMI = weight (kg) / height (m)2.   
 Waist circumference was measured to ensure that all male subjects less 
than 102 cm and that all female subjects were less than 88 cm.  The waist 
circumference was defined as the narrowest part of the torso (above the umbilicus 
and below the xiphoid process).  A horizontal Gulick measuring tape (Creative 
Health Products; Plymouth, USA) was used to determine circumference, and the 
measurement was recorded to the nearest 0.1 cm. 
 
Blood pressure and Pulse 
 Blood pressure and heart rate were measured with a Critikon automated 
Dinamap sphygmomanometer (Welch Allyn; Arden, USA) following 10 minutes 
of supine rest.  Blood pressure readings were obtained in both arms to determine 
if systolic blood pressure (SBP) was less than 130 mmHg and diastolic blood 
pressure (DBP) was less than 85 mmHg.  The resting heart rate was recorded as 
number of beats per minute. 
 
Ankle-Brachial Index 
   An ankle-brachial index (ABI) test was performed using the Doppler 
ultrasound technique to rule out the presence of peripheral arterial disease, 
defined as an ABI of ≤ 0.90 (54).  The brachial systolic pressures were obtained 
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as described above.  The ankle systolic pressures were taken simultaneously with 
each brachial pressure.  Specifically, a hand-held biodirectional Doppler machine 
(Hokanson; Bellevue, USA) was used to determine systolic pressure of the 
posterior tibialis and the dorsalis pedis arteries.  After finding the resting pulses at 
each location, a blood pressure cuff (Hokanson; Bellevue, USA) was secured 
around the ankle and inflated to approximately 200 mmHg.  The pressure in the 
cuff was slowly released at a rate of 2-4 mmHg per second.  The pressure 
corresponding with the first sound of a pulse was recorded as the systolic 
pressure.  The higher blood pressure of the two arteries was used as the ankle 
SBP.  The ABI was then calculated by the following equation:  ABI = Ankle SBP 
÷ Brachial SBP. 
 
 
Blood Markers 
 
Sample Preparation 
 
 On the first visit of the study, venapuncture was used to obtain the blood 
specimen for analysis of the blood markers.  Specifically, venous blood samples 
were collected from a vein in the antecubital space of either arm.  The blood was 
ejected into two types of vacutainers:  (1) a non-additive (red top) vacutainer for 
the CRP analysis and (2) a citrate anti-coagulant additive (1:9 vol of sample) 
siliconized (black top) vacutainer for the fibrinogen, t-PA, and PAI-1 analyses.    
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After the whole blood was collected into the vacutainer, the samples were 
centrifuged (Marathon 3200R; Fisher Scientific, USA) at 3000 X g for 15 
minutes.  The serum from the red top tubes (~10 mL of whole blood) was drawn 
and distributed into 1.0 ml aliquots in plastic microcentrifuge tubes.  The plasma 
from the black top tubes (~9 mL of whole blood) was distributed into 0.5 ml 
aliquots in plastic microcentrifuge tubes.  Care was taken to ensure a “platelet 
free" preparation, since platelets can release PAI-1.  The samples were then stored 
in an ultra-low freezer at -80°C, where they were batched until all samples were 
collected for analysis.  
 
C-Reactive Protein   
 A high-sensitivity Near Infrared Particles Immunoassay was used to 
quantify the concentration of C-reactive protein (CRP) from a serum sample of 
300 µl, the optimum sample volume for this specific assay.  A commercially 
available device, the SYNCHRON LX-20 (Beckman-Coulter; California, USA), 
was used to automatically perform the assay.  Prior to performing each assay, the 
SYNCHRON system was calibrated and a calibration curve was established.  To 
start the high-sensitivity assay, the SYNCHRON LX-20 combined one part of 
serum sample with 26 parts of the CRPH reagent, a pre-made solution consisting 
of an anti-CRP antibody-coated particle that causes a cloudy reaction when 
binding to CRP.  The change in absorbance, directly proportional to the 
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concentration of CRP, was monitored by the SYNCHRON system at 940 
nanometers and was used to calculate the CRP concentration based upon the pre-
determined calibration curve.  The “normal” reference range for concentrations of 
CRP using this high-sensitivity assay is 0.0 – 3.3 mg/L (16,76,129).   
 
Fibrinogen  
 The ZYMUTEST Fibrinogen (DiaPharma) kit is a two site enzyme-linked 
immunosorbent assay (ELISA) for measuring human Fibrinogen in plasma, or in 
any fluid where Fibrinogen can be present. This specific ELISA is designed with 
rabbit polyclonal antibodies and is affinity purified.  A standard curve, using the 
concentrations of 0, 5, 10, 25, and 50 ng/ml, was constructed on each microplate 
and was used for the assays.  At the start of the process, 200 µl of the standard 
solutions or the tested samples were introduced into the corresponding microplate 
well.  The microplate was mixed gently on a plate shaker and set to incubate for 
one hour at room temperature (18-25 °C).  All plate shakes for each ELISA were 
set to 600 rpm, unless otherwise noted.  After this first incubation period, the 
wells were emptied and subjected to five successive washings with the provided 
washing solution (20 fold diluted in distilled water).   
 Next, 200 µl of the Anti-Fibrinogen HRP immunoconjugate was 
introduced into the plate wells.  Again, the plate was gently mixed on a plate 
shaker and allowed to incubate for 1 hour at room temperature (18-25 °C).  The 
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microplate wells were washed another five times, as previously described.  
Immediately following the second wash, 200 µl of a tetramethylbenzidine (TMB) 
with hydrogen peroxide (H2O2) substrate was introduced into the wells.  This was 
allowed to develop a blue color in the wells, and should take approximately five 
minutes.  In the exact same fashion the TMB/H2O2 substrate was added, 50 µl of 
0.45 M sulfuric acid was added to the wells to stop the color development.  After 
letting the last step stabilize for 10 minutes, the microplate spectrophotometer 
analyzed the samples at 450 nm.   Fibrinogen concentration in normal human 
plasma is in the range 1.5 to 5 mg/ml, in which greater than 5 mg/ml is associated 
with inflammation. 
 
Tissue Plasminogen Activator 
 Biopool’s Chromolize™ t-PA (DiaPharma Group, Inc; Ohio, USA) is a 
commercially available bio-functional immunosorbent assay (BIA) intended for 
the quantitative determination of human tissue plasminogen activator activity in 
plasma.  All of the steps involved with this assay were performed at room 
temperature (18-25 °C).  A standard curve was included with each plate analysis, 
using known concentrations of 0, 0.5, 1.0, 1.5, 2.0 IU/ml for the standards.  A 
total of 100 µl of t-PA standards or 100 µl of sample to the microplate wells and 
the positions were recorded.  The plate was allowed to incubate for 20 minutes on 
a plate shaker at ambient temperature.  After this incubation period, the 
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supernatant was discarded by tapping onto an absorbent towel.  Following this 
step, the wells were filled completely with Phosphate, NaCl, EDTA, and Tween 
20 (PET) concentrate buffer and emptied to wash the wells 4 times.   
After the first washes, 50 µl of Lyophilised H-D-But-CHT-Lys-pNA and 
poly-D-lysine (substrate reagent) were added to each well using a repeating 
pipette.  Immediately following, 50 µl Lyophilised plasminogen and FDP 
(Plasminogen Reagent) were added to each well using the same technique, which 
was completed within 2 minutes.  Again, the plate incubated for 90 minutes at 
ambient temperature on a microtest plate shaker at 600 rpm.  Finally, 50 µl a stop 
solution (1.7 M acetic acid) was added to each well and allowed to mix on a 
microtest plate shaker for at least 15 seconds, forming a yellowish color.   
The absorbance was set at 405 nm on the spectrophotometer, and a 
“blank” was run against air.  Then, the absorbance in all wells was measured at 
405 nm. A second measurement may be made at 492 nm and these subtracted 
from the readings at 405 nm.  Paranitroanilide absorbs light at 405 nm, whereas 
the absorbance due to turbidity is approximately equal at 405 nm and 492 nm.  
Therefore, absorbance at 492 nm was measured and subtracted to correct for 
background due to turbidity.  For healthy humans the basal level is between 0.2-2 
IU/ml (38). 
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Plasminogen Activator Inhibitor – 1 
Biopool Chromolize™ PAI-1 (DiaPharma Group, Inc; Ohio, USA) is a bio 
immunoassay (BIA) for the quantitative determination of active human 
plasminogen activator inhibitor, type 1 (PAI-1) in human plasma.  With each 
assay, the PAI-1 standards were made for the PAI-1 concentrations of 0, 15, 30, 
and 50IU/ml and were used in the standard curve, which is used in the 
interpolation of PAI-1 activity in the patient’s plasma specimen.  After the 
standards were prepared, the wells in each microplate were reconstituted with 25 
µl of the PET buffer.  The plate was allowed to incubate on a microplate shaker at 
a speed of 600-800 r.p.m. for 2 minutes.  Exactly 25 µl of plasma samples or the 
PAI-1 Standards was added to each well, and the positions were recorded.  
Immediately following (not to exceed 1 minute), 25 µl of Conjugate was added to 
each well.   The plate then incubated for 30 minutes on a microplate shaker set at 
a speed of 600-800 r.p.m.  Then the contents were discarded, washed with the 
PET buffer and emptied onto an absorbent towel.  This washing process was 
repeated four times.  
 Next, 100 µl of the phosphate / citrate buffer with hydrogen peroxide 
(HRP) substrate to each well and the tray incubated for exactly five minutes on a 
shaker as described above.  The reaction was stopped by adding 100 µl of 1.6 M 
sulphuric acid to each well in the same order and speed as the substrate was 
added.  To quantify the PAI-1 in the specimen samples, the absorbance was set at 
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492 nm on the microplate spectrophotometer, with a “blank” against air being run 
first.  Following, the absorbance in all wells were measured at 492 nm.  The 
detection range for this specific assay is 2.0 to 50 IU/ml.  Using this assay, the 
expected concentration of PAI-1 in plasma samples seen healthy adults should be 
around 5.15 ± 7.13 (SD) IU/ml (38). 
 
Body Composition Assessment 
Dual-energy X-ray absorptiometry (DXA) was used to measure body fat 
mass and fat-free mass during the second visit of the study.  This DXA technique 
provides a body composition measurement, dividing the body into fat tissue, fat-
free tissue, and bone mineral.   
The Hologic QDR 4500 (Hologic Inc; Massachusetts, USA) DXA scanner 
is a fan beam scanner.  Fan beam scanners perform one or more sweeps across the 
patient instead of the two-dimensional scan required by pencil beam geometry, 
resulting in decreased scan times and higher image resolution (15). There is an 
exposure to radiation during a whole body DXA scan is approximately 1.0 mrem.  
The x-ray tube is equipped with a filter to convert the polychromatic X-ray beam 
into low (100 keV) and high-energy peaks (140 keV).  The scanning arm passes 
over the DXA bed and detects the x-ray energy that passes through the body in a 
posterior to anterior direction.  The attenuation of the x-ray has a direct 
relationship with the mass of the tissue through which it passes.  The QDR4500A 
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scanner has shown to be a highly reliable an accurate assessment of percent body 
fat (%BF), with a precision of <1 - 1.2 %BF (10,80).   
Prior to each scan, all subjects were instructed to remove any metal or 
other interfering objects, such as jewelry, from their body.  For all females, a 
human chorionic gonadotropin (HCG) test was completed to ensure they were not 
pregnant.  Subjects underwent a total body scan with a fan beam X-ray in the 
array mode, after being properly situated in the supine position on the DXA bed.   
All scan analyses were performed by the same qualified technician.  Quality 
Assurance and control phantom calibration scans were completed at the beginning 
of each test day.  
   
Ambulatory Physical Activity Assessment 
Ambulatory physical activity level was monitored for two to seven 
consecutive days (4.8 ± 1.0 days) by a StepWatch activity monitor (Cyma; 
Seattle, Washington) wrapped around the ankle using elastic straps above the 
lateral malleolus of the right leg.  The StepWatch activity monitor measured 
strides and minutes of ambulatory activity accumulated per day for activity at a 
lower cadence (<15 strides per minute), activity at a moderate cadence (≥15 and < 
30 strides per minute) and activity at a higher cadence (≥ 30 strides per minute), 
and total activity (the sum of activity at a lower, moderate, and a higher cadence). 
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Subjects were instructed to wear the device in this exact position, during 
their waking hours and to remove them before retiring to bed.  Additionally, the 
subjects were instructed to carry out their usual activities through the monitored 
period. The activity monitor was issued on the first visit and returned on the 
second visit, at which time the data was downloaded and recorded.  The step 
activity monitor is a highly reliable and validated method of quantifying of 
ambulatory physical activity (77,124). 
 
 
Statistical Analysis 
 
 In an initial analysis of the study data, a summary description of the 
population was made by presenting the gender specific mean, standard deviation, 
maximum, and minimum values for each variable.  All values were reported as 
the mean ± standard deviation (SD).  The data were graphed as a first examination 
of relationships between variables to reveal any outliers in the data set.  Outliers 
were checked as possible data entry errors. Errors were corrected or omitted. 
Outliers that were not errors were examined to determine their influence on the 
statistical results, by running the analyses with and without the outlier. Influential 
outliers were omitted from final analyses but noted and discussed.   
 To fully address the age associated changes in inflammation and 
fibrinolysis, subjects were grouped into one of three categories according to age:  
“Younger” = 20 – 39 years, “Middle Age” = 40 – 59 years, and “Older” = 60 
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years and greater.  An analysis of variance was used to detect mean differences 
among the three groups for all measured variables.  
 A correlation matrix correlating each variable with each other variable was 
constructed to examine pairwise relationships and dependencies between physical 
characteristics of the subjects, the blood concentrations of the inflammatory and 
fibrinolytic markers.  In particular, correlations between the independent variables 
identified redundant characteristics.  For example, if BMI and percent body fat are 
highly correlated, then we used the more descriptive variable (the larger absolute 
correlation) as a covariate in further statistical analyses. 
 Following these summary and investigational analyses, the primary 
analysis used a general linear model (GLM) to determine the significant 
predictors of levels for each marker of inflammation and fibrinolysis.  The initial 
independent variable was age and the outcome (dependent) was the serum 
concentration of inflammatory or fibrinolysis marker.  Physical characteristics 
(i.e., body composition, gender, and physical activity) found to significantly 
correlate with the concentration of each blood marker were entered as covariates 
into the statistical model to isolate the affect of age on inflammation and 
fibrinolysis. A p value was provided for each hypothesis test and an alpha = 0.05 
was used to define significance.    All statistical analyses were performed with the 
Statistical Package for the Social Sciences (SPSS, v. 11.5, Chicago, IL) software. 
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Statistical Power and Sample Size 
 Typically a relationship between an independent variable and a dependent 
variable is of interest if at least 25% of the variation in the dependent variable is 
attributable to variation in the independent variable, that is, r2 ≥ 0.25.  A power 
analysis was performed using the NESS-PASS statistical software package to 
determine the number of subjects needed to detect relationships at the significance 
level (alpha) of 0.05.  As shown in figure 2, it was determined that about 30 
subjects were necessary to detect a relationship of r2 ≥ 0.25, ensuring a power of 
80% (β = 0.20).  Because there are two gender groups, at least 30 males and 30 
females were needed.  The study aimed to recruit and complete testing on a total 
of 80 subjects (40 males, 40 females) to allow for loss of participants and/or data 
from the study.   
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Figure 2.  Results of the power calculations. 
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CHAPTER FOUR 
 
RESULTS 
 
 
 
 The purpose of this study was to investigate the relationship between age, 
whole body and trunk fat mass, physical activity level and blood levels of CRP, 
fibrinogen, t-PA, and PAI-1.  In order to accomplish this, 88 participants were 
enrolled in the study.  Of the total enrolled, six individuals were excluded from 
participating, as one person reported regular use of non-steroidal anti-inflammatory 
drug, one person did not show up for the second visit, one person reported a recent 
influenza vaccination, and three people had hypercholesterolemia.  Results of the 
remaining 82 participants are presented throughout the remainder of this chapter.   
 
 
Group Characteristics and Comparisons 
 
 Comparing Men and Women Subjects.  The means and standard deviations of 
the physical characteristics were calculated for the men and women and are 
presented in Table 1.  Independent t-tests between gender groups showed that the 
men were taller than the women (p < 0.001) and weighed more than the women (p < 
0.001).  The females had a higher resting pulse compared to men (p = 0.004) and a 
higher high-density lipoprotein (HDL) level than men (p = 0.013).  There were no 
differences (p > 0.05) between men and women on any other physical characteristic.   
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  Table 2 presents the body composition data for men and women.  The men 
had a greater waist circumference than the women (p < 0.001), but they had a lower 
percent fat in the trunk (p < 0.001) compared to the women.  Additionally, the 
percent of whole body fat was lower in men than in women (p < 0.001), as was the 
whole body fat mass (p < 0.001).  No differences were found between men and 
women in body mass index (BMI) or trunk fat mass (p > 0.05).  
 The ambulatory activity measurements were compared between men and 
women and are presented in Table 3.  Overall, the women accumulated more total 
minutes of daily ambulatory activity than the men (p = 0.046), as well as more 
minutes of activity at a lower cadence (p = 0.008).  The men were more sedentary 
than the women (p = 0.046).  The remaining ambulatory activity measurements were 
not significantly different (p > 0.05) between the men and women.   
 The blood marker concentrations in the men and women are compared in 
Table 4.  There was no difference in CRP values between the men and the women (p 
= 0.504).  Additionally, no significant differences were found between men and 
women in blood levels of fibrinogen (p = 0.700), tissue plasminogen activator (t-PA) 
(p = 0.984), or plasminogen activator inhibitor – 1 (PAI-1) (p = 0.453). 
Comparing Age Groups. To examine age-related differences in 
measurements, subjects were categorized into three groups according to age:  
“Younger” = 20 – 39 years, “Middle Age” = 40 – 59 years, and “Older” = 60 years 
and greater.  The number of men and women in each group is shown in Figure 3, and 
the physical characteristics of each age group are presented in Table 5.  One-way 
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ANOVAs revealed significant differences among the three age groups in systolic and 
diastolic blood pressure, total cholesterol, and low-density lipoprotein (LDL) level.  
More specifically, the older adults had a higher systolic blood pressure than the 
younger adults (p < 0.001) and middle age adults (p < 0.001), and a higher diastolic 
blood pressure than the younger adults (p = 0.004).  The older adults also had a 
higher total cholesterol (p<0.001) and LDL level (p<0.001) than the younger and 
middle age adults.   
  Body composition measurements were also examined by age group, as 
shown in Table 6.  Significant differences were found among the groups in waist 
circumference (p = 0.012), percent body fat (p = 0.001), body fat mass (p = 0.016), 
and the percent trunk fat (p < 0.001).  The younger adults had a smaller waist 
circumference than the middle age (p = 0.024) and older adults (p = 0.046).  
Additionally, the older adults had a higher percent body fat (p = 0.001), higher body 
fat mass (p = 0.014), and a higher percentage of trunk fat (p < 0.001) compared to 
the younger adults.  No significant differences were found in weight (p = 0.442), 
BMI (p = 0.125), or trunk fat mass (p = 0.054). 
  Table 7 shows the ambulatory activity measurements by age group.  Overall, 
there were no significant differences in activity measures among the younger, middle 
age, and older adults (p > 0.05). 
 The blood marker concentrations among the younger, middle age, and older 
adults are presented in Table 8.  Results from one-way ANOVA shows that the older 
age group had a significantly higher level of t-PA than the younger group (p = 
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0.042).  No significant differences were found among age groups in the 
concentrations of CRP (p = 0.413), fibrinogen (p = 0.231), and PAI-1 (p = 0.489). 
 
Correlations Among Blood Markers and Physical Characteristics 
 Age and Physical Characteristics. Pairwise correlations between age and 
physical characteristics are presented in Table 9.  As shown, age was positively 
related to systolic blood pressure (r = 0.573, p < 0.001), diastolic blood pressure (r = 
0.406, p < 0.001), total cholesterol (r = 0.333, p = 0.002), LDL level (r = 0.286, p = 
0.009), and HDL level (r = 0.231, p = 0.036).  The scatter plots examining age with 
physical characteristics to identify potential outliers in the data set are shown in 
Appendix I. 
 Age and Body Composition. Pairwise correlations between age and body 
composition also are presented in Table 9.  Age was positively related to waist 
circumference (r = 0.295, p = 0.007), percent of whole body fat (r = 0.401, p < 
0.001), whole body fat mass (r = 0.335, p = 0.002), percent trunk fat (r = 0.430, p < 
0.001), and trunk fat mass (r = 0.248, p = 0.025).  Body composition measurements 
were plotted against age (Appendix J) to identify potential outliers in the data set.  
 Age and Ambulatory Activity Measures. Pairwise correlations between age 
and ambulatory activity measures also are shown in Table 9.  The only activity 
measures that were related to age were the number of strides per day at a moderate 
cadence (r = 0.268, p = 0.016) and the number of minutes per day at a moderate 
cadence (r = 0.232, p = 0.037).   Physical activity measures were plotted against age 
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(Appendix K) to identify potential outliers in the data set.  The data for age vs. total 
strides per day, strides of activity at a lower cadence, and strides of activity at a 
moderate cadence all showed one outlier in the scatter plots.  After confirming that 
this was not a data entry error, the data point was removed from the data set and the 
correlations with age were repeated.  The correlation coefficient remained consistent 
with our initial analyses, therefore the outlying data point was included in the data 
set.   Later analyses for each blood marker were also done with and without the 
outlier to determine the influence, if any, on the blood marker concentrations.  
 Predictors of C-Reactive Protein.  CRP values for the entire group ranged 
from 0.2 mg/L to 10.4 mg/L, and are presented across age in Figure 4.  Upon 
reviewing the C-reactive protein (CRP) levels, one subject had a CRP value of 77.0 
mg/L.  This value lies nearly nine standard deviations above the mean CRP 
concentration for the sample (2.3 ± 8.5 mg/L).  This extremely high value is 
indicative of an underlying infection that went undetected during screening (129), 
which is part of the exclusion criteria of the study.  Thus, the data point was removed 
from the remaining analyses.   
 As shown in Table 9, CRP was not significantly correlated to age (r = -0.073, 
p = 0.519), but was correlated to total cholesterol (r = -0.338, p = 0.002) and HDL 
levels (r = -0.255, p = 0.022).  CRP also was significantly correlated to the body 
composition measures: BMI (r = 0.304, p = 0.006), waist circumference (r = 0.279, p 
= 0.012), percent body fat (r = 0.221, p = 0.048), percent trunk fat mass (r = 0.243, p 
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= 0.029), and trunk fat mass (r = 0.234, p = 0.036).  None of the ambulatory activity 
measures were related to CRP levels in the sample.  
 To reduce the number of covariates to be considered in a subsequent model, a 
correlation analysis was done between biologically correlated variables.  This 
secondary correlation analysis showed that HDL and total cholesterol were 
significantly correlated (r = 0.449, p < 0.001).  Therefore, HDL was used as a 
covariate in the GLM to assess the relationship between age and CRP.  All of the 
body composition measures were significantly related (p < 0.05) with one another.  
BMI, percent body fat and trunk fat mass were selected as covariates between body 
composition and CRP, as they were the strongest correlates with CRP.  All variables 
were entered one at a time into the GLM assessing the relation between age and CRP 
to determine which combination has the greatest confounding influence of CRP 
levels. 
 A general linear model (GLM) showed that CRP levels did not change with 
age (R2 = 0.011, p = 0.641).  BMI, percent body fat, trunk fat mass, and HDL were 
all entered separately into the general linear model (Appendix L) examining whether 
age was an independent predictor of CRP.  Individually, BMI was the most powerful 
predictor (Sum of Squares [SS] = 28.896; R2 = 0.095, p = 0.013) of all of the body 
composition measures.  The model was not changed after adding trunk fat mass (SS 
= 28.926; R2 = 0.083, p = 0.031) and percent body fat (SS = 29.344; R2 = 0.085, p = 
0.029).  Thus, BMI and HDL were the covariates in the final CRP model.  While the 
final model was significant (SS = 30.22; R2 = 0.077, p = 0.050), BMI, not age or 
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HDL, was found to be the only significant predictor (p = 0.036) of CRP levels.  
Lastly, there was no significant age by gender interaction in the model.   
 Predictors of Fibrinogen.  Fibrinogen values for the entire group averaged 
4.2 ± 1.7 IU/mL and ranged from 2.16 IU/mL to 13.35 IU/mL.  The fibrinogen value 
of 13.35 IU/ml was 5.4 standard deviations above the mean, and was removed from 
the data for the remaining analyses.  After removing this outlier, the fibrinogen 
values for the group averaged 4.1 ± 1.4 IU/mL and ranged from 2.16 IU/ml to 9.72.  
These data are presented across age in Figure 5.   
 Fibrinogen was not significantly correlated to age (r = -0.010, p = 0.951) 
(Table 9).  In contrast, fibrinogen concentration was related to strides per day of 
activity at a higher cadence (r = -0.242, p = 0.029), minutes per day of activity at a 
higher (r = -0.223, p = 0.045), and percent trunk fat (r = 0.238, p = 0.031).  After 
removing the outlier, fibrinogen levels also were correlated to resting heart rate (r = 
0.306, p = 0.005), percent body fat (r = 0.257, p = 0.020), body fat mass (r = 0.239, p 
= 0.026), percent trunk fat (r = 0.307, p = 0.004), trunk fat mass (r = 0.297, p = 
0.007), and strides per day of activity at a higher cadence (r = -0.225, p = 0.045).   
 A secondary correlation analysis showed the percent body fat correlated with 
body fat mass (r = 0.949, P < 0.001) and percent fat correlated with trunk fat mass (r 
= 0.761, p < 0.001).  To reduce the number of covariates, resting heart rate, percent 
body fat, percent trunk fat, and strides per day of activity at a higher cadence were 
selected as covariates for the GLM examining the relation between age and 
fibrinogen.   
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 In the initial GLM, age was not an independent predictor of fibrinogen 
concentrations (SS = 117.15; R2 = 0.131, p = 0.319) (Appendix M).  There was no 
significant age by gender interaction in the model.  Resting heart rate, percent body 
fat, percent trunk fat, and strides per day of activity at a higher cadence were all 
entered separately into the GLM (Appendix M).  Individually, heart rate was the 
most influential covariate (Sum of Squares [SS] = 125.91; R2 = 0.230, p = 0.117), 
however it was not significant.  The model only slightly changed after adding 
percent body fat, percent trunk fat and strides per day of activity at a higher cadence 
(SS = 128.62; R2 = 0.237, p = 0.226).   The final GLM showed that age was not an 
independent predictor of fibrinogen levels (p = 0.236), and that there was no 
significant age by gender interaction (p = 0.825) in the model.   
Predictors of Tissue Plasminogen Activator, Activity. The t-PA 
concentrations for the entire group (0.72 ± 0.44 IU/mL) ranged from 0.14 IU/mL to 
2.61 IU/mL.  Upon further review, one individual had a t-PA level of 2.61 IU/mL 
(4.3 standard deviations above the mean) and another had a t-PA level of 2.43 IU/ml 
(3.9 standard deviations above the mean).  Therefore, these outliers were excluded 
from the analyses.  The corrected t-PA concentrations for the entire group then 
averaged 0.68 ± 0.34 IU/mL and range from 0.14 IU/mL to 1.64 IU/mL. They are 
presented across age in Figure 6.   
 Initially, t-PA was correlated with age (r = 0.228, p = 0.042) (Table 9), and 
was negatively correlated with triglyceride level (r = -0.279, p = 0.012).  
Consequently, triglyceride concentration was used as a covariate in the GLM that 
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assessed the relationship between age and t-PA.   None of the other physical 
characteristics, measures of body composition or measures of ambulatory activity 
were significantly related to t-PA concentrations (p < 0.05).  These results were the 
same when examined with and without the outliers. 
 In contrast to the correlation analysis, the initial GLM showed that age was 
not a predictor of t-PA concentrations (SS = 6.38; R2 = 0.030, p = 0.567) (Appendix 
N).  The model was unchanged after adding triglyceride levels to the GLM (SS = 
6.38; R2 = 0.079, p = 0.636). There was no age by gender interaction (p = 0.525).   
Predictors of Plasminogen Activator Inhibitor -1, Activity.   The PAI-1 
concentrations for the entire group (6.47 ± 9.39 IU/mL) ranged from 0.00 IU/mL to 
40.03 IU/mL.  The subject with a PAI-1 level of 40.03 IU/mL was removed from the 
analysis, as the value was 4.0 standard deviations above the mean.  Thus, the 
corrected PAI-1 values for the group averaged 5.91 ± 7.58 IU/mL and ranged from 
0.00 IU/mL to 29.13 IU/mL.  The PAI-1 concentrations across age for the entire 
group are presented in Figure 7. 
 Before removing the outlier, PAI-1 concentrations were significantly 
correlated to triglyceride levels (r = 0.310, p = 0.005), HDL (r = -0.218, p = 0.049), 
BMI (r = 0.277, p = 0.012), waist circumference (r = 0.53, p = 0.022), and percent 
trunk fat (r = 0.245, p = 0.026).  Once the outlier was removed, PAI-1 was 
significantly correlated to weight (r = 0.262, p = 0.018), systolic blood pressure (r = 
0.221, p = 0.047), diastolic blood pressure (r = 0.275, p = 0.013), triglyceride level (r 
= 0.334, p = 0.002), HDL level (r = -0.280, p = 0.011), BMI (r = 0.377, p = 0.001), 
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waist circumference (r = 0.334, p = 0.002), percent body fat (r = 0.236, p = 0.034), 
body fat mass (r = 0.248, p = 0.026), percent trunk fat (r = 0.307, p = 0.005), and 
trunk fat mass (r = 0.264, p = 0.017).  PAI-1 concentrations were not significantly 
correlated (p > 0.05) with age or any of the ambulatory activity measures.   
 A secondary correlation analysis between biologically correlated variables 
was done to further reduce the number of covariates to be considered in a subsequent 
model.  Systolic blood pressure was highly correlated with diastolic blood pressure (r 
= 0.715, p < 0.001) and triglyceride level correlated with HDL level (r = -0.440, p < 
0.001).  BMI was significantly correlated with waist circumference (r = 0.864, p < 
0.001), percent body fat (r = 0.449, p < 0.001), body fat mass (r = 0.596, p < 0.001), 
percent trunk fat (r = 0.642, p < 0.001), trunk fat mass (r = 0.699, p < 0.001).  
Percent body fat was correlated with body fat mass (r = 0.932, p < 0.001) and 
percent trunk fat was correlated with trunk fat mass (r = 0.761, p < 0.001).  
Therefore, diastolic blood pressure, triglyceride levels, body fat mass, and percent 
trunk fat were selected as covariates for the GLM, as they were the strongest 
correlates with PAI-1.   
  Age was not an independent predictor of PAI-1 concentrations in the initial 
GLM (SS = 3199.94; R2 = 0.158, p = 0.736).  Diastolic blood pressure, triglyceride 
levels, body fat mass, and percent trunk fat were all entered separately into the GLM 
(Appendix O).  Diastolic blood pressure (SS = 388.92; R2 = 0.105, p = 0.012), and 
percent trunk fat (SS = 247.11; R2 = 0.001, p = 0.051) were the most influential 
factors in the GLM.  Therefore, these variables were entered as covariates in the final 
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model to determine if age is an independent predictor of PAI-1 levels.  The final 
model showed that age was not an independent predictor of PAI-1 concentrations 
(SS = 3654.78; R2 = 0.137, p = 0.333).  There was no significant age by gender 
interaction (p = 0.836) in the model.   
 77
Table 1 displays the physical characteristics of the male and female subjects.  The p 
value represents the significance between the two groups. 
 
 
Mean ± s.d. Min. Max. Mean ± s.d. Min. Max. p value
Age (Years) 45.9 ± 18.2 22 89 47.9 ± 17.3 21 81 0.611
179 ± 5.9 166 196 166 ± 6.6 153 185 < 0.001
81.4 ± 11.5 57.1 111 66.6 ± 10.9 49.2 93.1 < 0.001
120 ± 14 98 177 115 ± 13 94 150 0.104
72 ± 8 54 84 72 ± 8 52 86 0.863
55 ± 7 41 68 61 ± 11 42 92 0.004
Total Cholesterol (mg/dL) 181 ± 34 104 256 191 ± 49 64 331 0.247
Triglyceride ( mg/dL) 81 ± 44 22 245 76 ± 34 31 154 0.598
Low-Density Lipoproteins (mg/dL) 114 ± 28 53 178 120 ± 39 69 251 0.415
High-Density Lipoproteins (mg/dL) 50 ± 13 26 80 58 ± 17 38 111 0.013
LDL / HDL Ratio 2.4 ± 1 1.1 6.4 2.1 ± 0.8 0.5 4.2 0.108
Males (n = 40) Females (n = 42)
Height (cm)
Resting Heart Rate (bpm)
Weight (Kg)
Systolic Pressure (mmHg)
Diastolic Pressure (mmHg)
 
 
“s.d.” = standard deviation; “min.” = Minimum value; “max.” = Maximum value 
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Table 2 displays the body composition measures of the male and female subjects.  
The p value represents the significance between the two groups. 
 
Mean ± s.d. Min. Max. Mean ± s.d. Min. Max. p value
(Kg/m 2 )
(Centimeters)
0.5253031 20301
< 0.001
Trunk Fat Mass (g) 8506 ± 5888 2431 27656 9277 ± 5046
9.8 10.7 45.27.2 41.8 27.8 ±Trunk Fat (%) 19.0 ± 8.3
< 0.00112736 45063
< 0.001
Whole Body Fat (g) 16512 ± 7498 6413 36380 24581 ± 7913
7.5 15.3 46.29.3 36.8 31.1 ±Whole Body Fat (%) 19.1 ± 6.8
< 0.00149.2 93.1
< 0.001
0.1
Body Weight (Kg) 81.4 ± 11.5 57.1 111.0 66.6 ± 10.9
10.7 64.0 104.3
4.0 18.6 33.9
Waist Circumference 87.0 ± 9.5 72.6 112.0 78.6 ±
Males (n = 40) Females (n = 42)
Body Mass Index 25.5 ± 3.2 20.3 32.6 24.2 ±
 
 
“s.d.” = standard deviation; “min.” = Minimum value; “max.” = Maximum value 
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Table 3 displays the ambulatory activity measurements of the male and female 
subjects.  The p value represents the significance between the two groups. 
 
Mean ± s.d. Min. Max. Mean ± s.d. Min. Max. p value
Strides / Day 6049 ± 3342 1760 20411 5924 ± 1893 2545 11245 0.836
Minutes / Day 344.0 ± 117.2 103.6 572.9 394.9 ± 108.8 201.8 650.7 0.046
Strides / Day 1427 ± 914 279 5774 1589 ± 544 664 3062 0.335
Minutes / Day 207.3 ± 72.8 40.5 374.7 253.9 ± 80.8 103.6 496.6 0.008
Strides / Day 1776 ± 1078 391 6371 1892 ± 780 783 4007 0.580
Minutes / Day 78.6 ± 39.4 17.5 200.8 87.7 ± 34.8 36.5 181.1 0.275
Strides / Day 2846 ± 1948 529 9363 2443 ± 1162 441 5341 0.260
Minutes / Day 63.2 ± 42.5 19.9 199.9 53.3 ± 24.0 11.7 124.5 0.199
Minutes / Day 1096.0 ± 117.2 867.1 1336.4 1045.1 ± 108.8 789.3 1238.2 0.046
Higher Activity
Sedentary Time
Males (n = 40) Females (n = 42)
Total Activity
Lower Activity
Moderate Activity
  
 
“s.d.” = standard deviation; “min.” = Minimum value; “max.” = Maximum value. 
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Table 4 displays the blood marker concentrations in the male and female subjects.  
The p value represents the significance between the two groups. 
Mean ± s.d. Min. Max. Mean ± s.d. Min. Max. p value
C-Reactive Protein 
(mg/L)
Fibrinogen 
(IU/mL)
(IU/mL)
(IU/mL)
0.20 10.40
Males (n = 40) Females (n = 42)
1.20 ± 1.40 0.20 6.80 ± 0.504
4.30 ± 2.08 2.16 13.35 4.15 ±
1.90
0.700
0.14 2.61 0.68
1.50
tPA  Activity 0.67 ± 0.35
9.72
± 0.18 1.30
1.30 2.55
0.00 29.13 0.453
0.32
7.80
0.984
PAI-1 Activity 7.04 ± 9.08 0.00 40.03 5.60 ±
 
 
 81
Figure 3 is the number of participants in each age group (by decade). 
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Table 5 displays the physical characteristics of the younger, middle age, and older 
adults.  The p value represents the significance between the three age groups. 
 
Younger Middle Age Older p value
173.0 ± 9.3 171.7 ± 7.9 171.2 ± 9.8 0.743
71.4 ± 12.3 75.9 ± 14.4 74.2 ± 13.7 0.442
112 ± 7 116 ± 11 129 ± 16*† < 0.001
69 ± 7 72 ± 8 76 ± 7* 0.006
58 ± 11 56 ± 9 62 ± 10 0.092
173 ± 40 178 ± 30 215 ± 47*† < 0.001
83 ± 47 72 ± 38 81 ± 28 0.528
110 ± 31 107 ± 23 140 ± 40*† < 0.001
50 ± 11 56 ± 18 59 ± 16 0.098HDL (mg/dL)
Height (cm)
Weight (kg)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Resting Heart Rate (bpm)
Total Cholesterol (mg/dL)
Triglyceride (mg/dL)
Age Group 
LDL (mg/dL)
 
LDL = low density lipoproteins; HDL = high-density lipoproteins; BP = blood 
pressure.  * denotes a significant difference from the younger adults.  † denotes a 
significant difference from the middle age adults.
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Table 6 displays the body composition measures of the younger, middle age, and 
older adults.  The p value represents the significance between the two groups. 
  
Younger Middle Age Older p value
71.4 ± 12.3 75.9 ± 14.4 74.2 ± 13.7 0.442
23.8 ± 3.4 25.6 ± 4.0 25.2 ± 3.2 0.125
78.1 ± 9.3 85.4 ± 11.7* 85.4 ± 10.2* 0.012
21.1 ± 9.1 25.4 ± 8.1 30.5 ± 8.8* 0.001
17.4 ± 8.3 21.3 ± 7.7 24.2 ± 9.2* 0.016
18.5 ± 9.7 23.9 ± 9.3 29.6 ± 8.2* < 0.001
7.3 ± 5.8 8.9 ± 5.4 11.0 ± 4.6 0.054Trunk Fat Mass (kg)
Waist Circumference (cm)
Whole Body Fat (%)
Body Fat Mass (kg)
Trunk Fat (%)
Age Group 
Weight (kg)
BMI (kg/m 2 )
 
 
BMI = body mass index.  * significantly different from younger adults (p < 0.017)
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Table 7 displays the ambulatory activity measurements of the younger, middle age, 
and older adults.  The p value represents the significance between the three age 
groups. 
 
 
SAM Data averaged per day Younger Middle Age Older p value
Strides / Day 5697 ± 2421 6116 ± 1918 6207 ± 3793 0.760
Minutes / Day 371 ± 114 379 ± 117 356 ± 118 0.794
Lower Activity
Strides / Day 1396 ± 479 1547 ± 678 1613 ± 1085 0.560
Minutes / Day 234 ± 69 238 ± 85 217 ± 88 0.636
Moderate Activity
Strides / Day 1670 ± 832 1795 ± 692 2111 ± 1271 0.238
Minutes / Day 77 ± 38 82 ± 31 92 ± 43 0.362
Higher Activity
Strides / Day 2631 ± 1719 2774 ± 1261 2484 ± 1876 0.818
Minutes / Day 59 ± 35 59 ± 24 56 ± 45 0.952
Sedentary Time
Minutes / Day 1069 ± 114 1061 ± 117 1083 ± 118 0.794
Age Group
Total Activity
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Table 8 displays the blood marker concentrations among the younger, middle age, 
and older adults.  The p value represents the significance among the three age 
groups. 
Younger Middle Age Older p value
1.68 ± 2.41 1.14 ± 1.16 1.20 ± 0.77 0.413
3.87 ± 1.44 3.92 ± 1.48 4.70 ± 1.03 0.231
0.590 ± 0.261 0.657 ± 0.342 0.825 ± 0.387 0.042
4.95 ± 6.43 6.45 ± 8.09 6.49 ± 8.52 0.489PAI-1 (Activity)(IU/mL)
Age Group 
CRP (mg/L)
Fibrinogen(IU/mL)
tPA (Activity)(IU/mL)
 
CRP = C-reactive protein; t-PA = tissue plasminogen activator; PAI-1 = 
plasminogen activator inhibitor-1.
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Table 9 is the bivariate correlations between age, the blood marker concentrations 
and all measured variables for the entire group. 
Age CRP Fibrinogen t-PA PAI-1
Age (Years) -- -0.073 0.206 0.228* 0.084
Height (cm) -0.126 -0.103 0.022 -0.010 -0.038
Weight (Kg) 0.073 0.162 0.114 -0.145 0.262*
Systolic Pressure (mmHg) 0.573** -0.066 0.116 -0.009 0.221*
Diastolic Pressure (mmHg) 0.406** -0.077 0.083 -0.110 0.275*
Resting Heart Rate (bpm) 0.149 0.091 0.306** 0.043 0.147
Total Cholesterol 0.333** -0.338** -0.02 0.156 -0.082
Triglyceride 0.000 0.136 0.038 -0.279* 0.334**
Low-Density Lipoproteins 0.286** -0.155 0.030 0.181 -0.049
High-Density Lipoproteins 0.231* -0.255* -0.066 0.117 -0.280*
LDL / HDL Ratio 0.079 0.074 0.006 0.033 0.136
Body Mass Index (Kg/m 2 ) 0.184 0.304** 0.125 -0.214 0.377**
Waist Circumference (cm) 0.295** 0.279* 0.152 -0.146 0.334**
Whole Body Fat (%) 0.401** 0.221* 0.257* -0.065 0.236*
Whole Body Fat (g) 0.335** -0.073 0.239* -0.102 0.248*
Trunk Fat (%) 0.430** 0.243* 0.307** -0.105 0.319**
Trunk Fat Mass (g) 0.248* 0.234* 0.297** -0.142 0.264*
Total Steps per Day 0.122 -0.125 -0.167 0.051 -0.116
Total Minutes per Day 0.022 -0.003 -0.106 0.078 -0.187
Low Steps per Day 0.164 -0.030 -0.043 0.132 -0.205
Low Minutes per Day 0.138 0.074 -0.039 0.072 -0.200
Moderate Steps per Day 0.268* -0.094 -0.062 0.108 -0.113
Moderate Minutes per Day 0.232* -0.089 -0.058 0.117 -0.123
High Steps per Day -0.027 -0.141 -0.225* -0.039 -0.034
High Activity Minutes per Day -0.002 -0.136 -0.203 -0.040 -0.042
Sedentary Minutes per Day -0.022 0.003 0.106 -0.078 0.187  
 
CRP = C-reactive protein; t-PA = tissue plasminogen activator; PAI-1 = 
plasminogen activator inhibitor – 1; LDL = low density lipoprotein; HDL = high 
density lipoprotein.  * p < 0.05, ** p < 0.01.
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Figure 4 is a scatter plot figure for CRP (C-reactive protein) values (y axis) across 
age (x axis) for the entire group.   
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Figure 5 is a scatter plot figure for fibrinogen concentrations (y axis) across age (x 
axis) for the entire group.   
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Figure 6 is a scatter plot figure for tissue plasminogen activator (t-PA) 
concentrations (y axis) across age (x axis) for the entire group.   
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
0 10 20 30 40 50 60 70 80 90 10
Age (Years)
tP
A
 L
ev
el
 (I
U
/m
L)
0
 
 
 90
Figure 7 is a scatter plot figure for plasminogen activator inhibitor – 1 (PAI-1) 
concentrations (y axis) across age (x axis) for the entire group.   
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
 The main purpose of this investigation was to determine if age is associated 
with blood concentrations of C-reactive protein (CRP), fibrinogen, tissue 
plasminogen activator (t-PA), and plasminogen activator inhibitor – 1 (PAI-1), 
independent of body fat and physical activity levels.  The primary finding of the 
current study shows that age is not independently associated with blood 
concentrations of CRP, fibrinogen, t-PA or PAI-1.  Additionally, this study revealed 
that BMI is a predictor of CRP levels, but not of markers of fibrinolysis. 
 
Aging and Inflammation 
 These results show that CRP concentrations did not increase with advancing 
age, which conflicts with previous claims.  Many studies conclude that aging is 
associated with increased plasma levels of CRP, TNF-α, and IL-6 (9,21,23).  In one 
of the largest age ranges examined (20 to 102 years of age), CRP and IL-6 were 
found to be significantly higher in the age groups 65 years of age and older in both, 
males and females even after adjusting for the existing clinical conditions (i.e., 
hypertension, hypercholesterolemia) (48).  But, the researchers failed to account for 
varying body size and physical activity status.   
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Another study comparing older and younger adults who were apparently 
healthy (9) carefully excluded for any disorders that could affect CRP levels.  
However, they did not account for blood pressure, cholesterol levels (or pertaining 
medications), physical activity levels, or body composition.  The failure to control 
for such potential covariates limits the conclusion that there are age-association 
changes in inflammatory status.  This study not only excluded subjects presenting 
with any co-existing clinical conditions, but also further adjusted for varying body 
size, body compositions, and physical activity levels.  To date, this is one of the most 
complete examinations of the independent association between age and 
inflammation.   
 There also have been previous reports that did not shown an increase in 
inflammation with age.  In the Framingham heart study, no differences were found in 
circulating TNF-α and IL1β between elderly adults and a younger, control group 
(115).  The Framingham findings are consistent with the findings of this study that 
inflammatory activity does not change with age.  Furthermore, the lack of an age-
related change in inflammatory markers suggests that inflammation does not 
independently increase the risk of cardiovascular disease as people age.  Instead, the 
prevention of atherosclerotic development should focus more on the increasing 
prevalence of co-morbid conditions (e.g. diabetes and hypertension) that occur with 
advancing age.  
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Aging and Fibrinolysis 
The analysis between age groups did reveal significantly higher levels of t-
PA in the older adults compared to younger adults (p = 0.042).  Additionally, this 
study found a correlation between age and t-PA (r = 0.228, p = 0.042).  Two 
previous reports show that t-PA release is blunted in older adults (36,127); however, 
they also reported the potential impact of habitual exercise on hemostatic conditions.   
Age is associated with decreased physical activity, decreased t-PA levels, and 
a higher incidence of thrombosis (36).  In this study, the older group had higher t-PA 
levels than expected and it was found that the strides and minutes of ambulatory 
activity at a moderate cadence per day increased with age.  Higher levels of physical 
activity have the potential to blunt the decrease in t-PA that is normally associated 
with age (36,127).  The higher levels of ambulatory physical activity measured 
among the older adults in this study also may help explain why the expected 
associations between age and inflammation and fibrinolysis were not present.  Thus, 
the adverse age-associated impact on fibrinolysis, however great it may be, appears 
to be either attenuated or absent in highly physically active individuals.   
A more in-depth analysis did not show a change in concentrations of 
fibrinogen, t-PA or PAI-1 with increasing age.  These results contradict the positive 
correlation between age and the occurrence of thrombosis that has been presented 
over the past couple of decades (36,148).  These studies showed a dramatic increase 
in PAI-1 and a decrease in t-PA activity with increasing age.  As previously 
suggested, the lack of change in fibrinolytic activity with age that was found in this 
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study may be a consequence of the higher physical activity levels that were 
maintained by the older adults in this study. 
While there could be a primary affect of aging, the data showing that 
increasing physical activity levels negate this affect introduce new factors that, at 
minimum, call this relation into question (36,127).  These studies in combination 
with the findings of this study raise the question if there is truly an age effect on 
fibrinolytic activity, or whether fibrinolysis is more of a result of typical age-related 
declines in physical activity patterns.   
 
Other Factors and Inflammation 
 Lipids. There were several factors found to be significantly related to CRP 
levels in this investigation.  First, CRP levels were inversely related to total 
cholesterol (r = -0.338, p = 0.002) and HDL levels (r = -0.255, p = 0.022).  HDL 
levels have previously been shown to be negatively correlated to CRP concentrations 
(100).  Most likely, the correlation between HDL and CRP explain the negative 
association between total cholesterol and CRP, as HDL is a component of total 
cholesterol levels.  This suggests that higher total cholesterol levels are probably not 
associated with lower levels of inflammation.  However, this negative correlation 
between HDL & CRP may help explain the link between high HDL levels and the 
associated decrease in risk for cardiovascular disease. 
 Obesity and Body Composition. Obesity has been consistently associated 
with generalized, low-grade inflammation (29,86).  In the current study, CRP levels 
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were also related to several measures of body composition.  BMI and waist 
circumference were positively related to CRP concentrations.  Overall, it was found 
that BMI is an independent predictor of CRP levels (p = 0.038) in healthy adults.  
Similar investigations have also shown CRP concentrations were significantly 
correlated with BMI, waist circumference, and waist-to-hip ratio (100,121,150,151).   
 Percent body fat, a more precise measure of body composition, also 
correlated positively with levels of CRP (r = 0.221, p = 0.048), as did percent trunk 
fat and trunk fat mass.  These results are not surprising, as previous research has 
shown that adipocytes can produce CRP, TNF- and IL-6 (34,68,87,132).  
Furthermore, the age-associated increase in body fat (55,98) may be an important 
source of increased circulating levels of inflammatory markers in the older 
population (63).  More importantly, this adds to the growing body of literature 
showing a link between obesity and inflammation, and strengthens the notion that 
inflammation may be the mechanistic link between obesity, and specifically 
abdominal obesity, and cardiovascular disease.   
 
Other Factors and Fibrinolysis 
 Lipids. Individuals with high triglyceride and low HDL levels were found to 
have high PAI-1 serum levels (93,106).  The findings of this study support these 
results, showing that triglyceride levels were positively related to PAI-1 levels (r = 
0.334, p = 0.002) and negatively related to t-PA levels (r = -0.279, p = 0.012).  
Additionally, HDL levels were negatively related to PAI-1 levels (r = -0.280, p = 
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0.011).  As shown by Orem et al (93) , successful lipid lowering therapy can improve 
fibrinolytic activity by increasing t-PA and decreasing PAI-1, suggesting that 
correcting dyslipidemia can reduce the risk of thrombosis formation.   
  Blood Pressure.  PAI-1 concentration was also positively related to systolic 
(r = 0.221, p = 0.047) and diastolic blood pressure (r = 0.275, p = 0.013).  
Hypertension, an established risk factor for acute coronary events, has been linked to 
impaired fibrinolysis in men and women (25,53,103,128).  As impaired fibrinolysis 
can lead to thrombosis (25,53), these data collectively provide another potential 
mechanism by which hypertension contributes to the pathogenesis of cardiovascular 
disease in hypertensive patients. 
 Obesity and Body Composition. As expected, BMI was directly related to 
PAI-1 levels (r = 0.377, p = 0.001), which indicates a decrease in fibrinolytic activity 
with increasing BMI.  Furthermore, these results show that fibrinogen and PAI-1 
were elevated with increases in more specific measures of whole body fatness, such 
as percent body fat and body fat mass.  The results of the current study agree with 
numerous previous studies (78,81,133), suggesting that the bridge between obesity 
and cardiovascular disease is becoming better defined.   From a clinical perspective, 
it is encouraging to learn that acute weight loss in obese individuals has been shown 
to improve fibrinolytic activity (29,78) and, in turn, decrease the risks of thrombus 
related accidents.   
 PAI-1 levels were also positively associated with waist circumference (r = 
0.334, p = 0.002).  More specifically, it was found that fibrinogen and PAI-1 levels 
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were positively related to percent trunk fat and trunk fat mass.  This suggests that 
abdominal adiposity may contribute to increased levels of PAI-1, the major inhibitor 
of fibrinolysis.  While fat distribution has been suggested to influence fibrinolytic 
activity (78,81,134), more studies are needed to clarify to the association between 
abdominal adiposity and fibrinolytic activity. 
 
Study Limitations 
 This study is not without its limitations.  This study used a cross-sectional 
design which does not allow for a causal link to be established between aging and 
inflammation or fibrinolysis.  The participants in this study, particularly the older 
adults, were extremely healthy volunteers and, thus, may not be representative of the 
general population around the Oklahoma City metropolitan area, which in other 
studies may be considered a limitation.  However, the rigor of the exclusion criteria 
was necessary to isolate the effect of age rather than other confounding factors 
commonly associated with age.  The sample was largely Caucasian.  Because of this, 
the results can not be generalized to adults from minority populations.   
 Another limitation is that the StepActivity Monitor is not waterproof and it is 
worn on the ankle, so water and upper body activity were not quantified throughout 
the monitoring period.  All subjects were questioned about their physical activity 
regimen, however, and only one participant engaged in water activity during the 
monitoring time period.  The most serious limitation related to the measurement of 
physical activity is that it is likely that a selection bias exists in this study, as only the 
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high-active elderly may have agreed to participate whereas low/moderate active 
younger subjects may not have volunteered.   
 Also, the dietary intake of subjects was not monitored in this study.  It has 
been shown that people on low fat diets have significantly improved fibrinolytic 
activity (118).  All of our subjects were tested in a fasted state, but the long-term 
dietary habits, including regular fat intake, is unknown.  By excluding for high 
cholesterol and high blood pressure, we also may have excluded for poor dietary 
habits as well.   
  
Conclusions 
 In summary, study results show that age is not independently associated with 
blood concentrations of CRP, fibrinogen, t-PA or PAI-1.  It can therefore be 
concluded that aging is not associated with inflammation and impaired fibrinolysis in 
subjects carefully screened for co-morbid conditions and cardiovascular risk factors.  
While blood pressure, cholesterol levels and measures of body composition were 
significantly related to markers of inflammation and fibrinolysis, BMI was found to 
be an independent predictor of only CRP, not of fibrinolytic markers.  Finally, it is 
speculated that previous observations of age-related changes in inflammation 
(9,21,22,23) and fibrinolysis (36,148) resulted from the variance in body 
composition, physical activity and co-existing clinical conditions that occur with 
aging. 
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Clinical Significance 
 This study indicates that inflammatory and fibrinolytic activity does not 
change with increasing age.  However, it was observed that inflammation and 
fibrinolysis were associated with high blood pressure, high cholesterol levels, and 
measures of body fatness, which provides a possible explanation for the discrepancy 
between our findings and those of previous studies which did not control for such 
factors.   
Furthermore, the maintenance of physical activity levels across the age range 
found in this sample suggests that physical activity may provide a protective effect 
against the age-related changes in inflammatory and fibrinolytic activity previously 
shown.  Regardless, blood pressure, cholesterol, body composition and physical 
activity levels are all manageable.  These results suggest that improving these 
problems will reduce the risk of developing cardiovascular disease by reducing 
inflammation and increasing fibrinolytic activity.  Combined with existing research, 
this study ultimately suggests that the risks associated with atherosclerotic disease 
are modifiable, not inevitable. 
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APPENDIX J 
 
Scatter Plots 
Age vs. Body Composition Measurements 
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APPENDIX K 
 
Scatter Plots 
Age vs. Physical Activity Measurements 
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Age vs. Minutes of Activity a Day
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Age vs. Minutes of Moderate Activity
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Age vs. Sedentary Time - Whole
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APPENDIX L 
 
General Linear Model Results 
Sum of Squares 
for 
C-Reactive Protein 
 
 158
Tests of Between-Subjects Effects
Dependent Variable: crp
2.541a 2 1.271 .448 .641
28.103 1 28.103 9.905 .002
1.271 1 1.271 .448 .505
1.358 1 1.358 .479 .491
221.297 78 2.837
372.950 81
223.839 80
Source
Corrected Model
Intercept
age
sex
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .011 (Adjusted R Squared = -.014)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: crp
21.523a 3 7.174 2.731 .050
1.013 1 1.013 .386 .536
8.978 1 8.978 3.417 .068
18.982 1 18.982 7.224 .009
4.366 1 4.366 1.662 .201
202.315 77 2.627
372.950 81
223.839 80
Source
Corrected Model
Intercept
age
perbfat
sex
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .096 (Adjusted R Squared = .061)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: CRP
16.938a 3 5.646 2.101 .107
13.638 1 13.638 5.075 .027
3.881 1 3.881 1.444 .233
14.397 1 14.397 5.358 .023
.921 1 .921 .343 .560
206.901 77 2.687
372.950 81
223.839 80
Source
Corrected Model
Intercept
AGE
TRNKFAT
SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .076 (Adjusted R Squared = .040)a. 
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Tests of Between-Subjects Effects
Dependent Variable: crp
28.896a 3 9.632 3.804 .013
6.962 1 6.962 2.750 .101
3.802 1 3.802 1.502 .224
26.354 1 26.354 10.410 .002
5.000 1 5.000 1.975 .164
194.943 77 2.532
372.950 81
223.839 80
Source
Corrected Model
Intercept
age
bmi
sex
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .129 (Adjusted R Squared = .095)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: crp
29.344a 4 7.336 2.867 .029
4.018 1 4.018 1.570 .214
4.073 1 4.073 1.592 .211
.448 1 .448 .175 .677
7.821 1 7.821 3.056 .084
.346 1 .346 .135 .714
194.494 76 2.559
372.950 81
223.839 80
Source
Corrected Model
Intercept
age
perbfat
bmi
sex
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .131 (Adjusted R Squared = .085)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: CRP
28.926a 4 7.231 2.820 .031
4.079 1 4.079 1.591 .211
3.809 1 3.809 1.485 .227
.030 1 .030 .012 .914
11.988 1 11.988 4.674 .034
4.394 1 4.394 1.713 .194
194.913 76 2.565
372.950 81
223.839 80
Source
Corrected Model
Intercept
AGE
TRNKFAT
BMI
SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .129 (Adjusted R Squared = .083)a. 
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Tests of Between-Subjects Effects
Dependent Variable: crp
19.830a 3 6.610 2.495 .066
44.282 1 44.282 16.713 .000
.001 1 .001 .001 .981
17.289 1 17.289 6.525 .013
5.275 1 5.275 1.991 .162
204.009 77 2.649
372.950 81
223.839 80
Source
Corrected Model
Intercept
age
hdl
sex
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .089 (Adjusted R Squared = .053)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: crp
33.767a 4 8.442 3.375 .013
.252 1 .252 .101 .752
1.183 1 1.183 .473 .494
13.937 1 13.937 5.573 .021
4.871 1 4.871 1.948 .167
7.060 1 7.060 2.823 .097
190.071 76 2.501
372.950 81
223.839 80
Source
Corrected Model
Intercept
age
bmi
hdl
sex
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .151 (Adjusted R Squared = .106)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: CRP
30.216a 5 6.043 2.341 .050
3.887 1 3.887 1.506 .224
3.337 1 3.337 1.293 .259
4.203 1 4.203 1.628 .206
.073 1 .073 .028 .867
11.764 1 11.764 4.557 .036
1.290 1 1.290 .500 .482
193.623 75 2.582
372.950 81
223.839 80
Source
Corrected Model
Intercept
SEX
AGE
TRNKFAT
BMI
SEX * AGE
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .135 (Adjusted R Squared = .077)a. 
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APPENDIX M 
 
General Linear Model Results 
Sum of Squares 
for 
Fibrinogen 
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Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
117.145a 58 2.020 1.209 .319
1154.043 1 1154.043 690.579 .000
101.029 44 2.296 1.374 .213
.138 1 .138 .082 .777
15.521 13 1.194 .714 .731
36.765 22 1.671
1524.217 81
153.909 80
Source
Corrected Model
Intercept
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .761 (Adjusted R Squared = .131)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
125.907a 59 2.134 1.600 .117
.114 1 .114 .085 .773
8.762 1 8.762 6.571 .018
96.156 44 2.185 1.639 .111
1.140 1 1.140 .855 .366
15.252 13 1.173 .880 .584
28.003 21 1.333
1524.217 81
153.909 80
Source
Corrected Model
Intercept
PULSE
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .818 (Adjusted R Squared = .307)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
122.585a 59 2.078 1.393 .202
6.022 1 6.022 4.037 .058
5.441 1 5.441 3.647 .070
91.567 44 2.081 1.395 .207
3.888 1 3.888 2.606 .121
14.560 13 1.120 .751 .698
31.324 21 1.492
1524.217 81
153.909 80
Source
Corrected Model
Intercept
PERBFAT
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .796 (Adjusted R Squared = .225)a. 
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Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
122.794a 59 2.081 1.405 .196
18.289 1 18.289 12.343 .002
5.649 1 5.649 3.813 .064
91.148 44 2.072 1.398 .205
2.536 1 2.536 1.712 .205
13.976 13 1.075 .726 .721
31.116 21 1.482
1524.217 81
153.909 80
Source
Corrected Model
Intercept
PERFTRK
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .798 (Adjusted R Squared = .230)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
117.947a 59 1.999 1.112 .411
170.928 1 170.928 95.072 .000
.619 1 .619 .344 .564
96.852 44 2.201 1.224 .319
.217 1 .217 .120 .732
13.405 13 1.031 .574 .847
35.958 20 1.798
1507.863 80
153.905 79
Source
Corrected Model
Intercept
STPHIDAY
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .766 (Adjusted R Squared = .077)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
126.501a 60 2.108 1.538 .143
.019 1 .019 .014 .907
3.707 1 3.707 2.705 .116
.594 1 .594 .434 .518
90.073 44 2.047 1.494 .167
1.721 1 1.721 1.256 .276
12.857 13 .989 .722 .723
27.408 20 1.370
1524.217 81
153.909 80
Source
Corrected Model
Intercept
PULSE
PERFTRK
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .822 (Adjusted R Squared = .288)a. 
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Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
126.540a 61 2.074 1.440 .190
.001 1 .001 .001 .982
3.736 1 3.736 2.594 .124
.175 1 .175 .121 .731
.039 1 .039 .027 .871
90.044 44 2.046 1.421 .205
.246 1 .246 .171 .684
12.765 13 .982 .682 .757
27.369 19 1.440
1524.217 81
153.909 80
Source
Corrected Model
Intercept
PULSE
PERFTRK
PERBFAT
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .822 (Adjusted R Squared = .251)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: FIBRIN
128.624a 62 2.075 1.395 .226
.018 1 .018 .012 .913
4.991 1 4.991 3.356 .085
1.204 1 1.204 .810 .381
.733 1 .733 .493 .492
.061 1 .061 .041 .842
90.588 44 2.059 1.384 .236
.001 1 .001 .000 .985
11.548 13 .888 .597 .825
25.281 17 1.487
1507.863 80
153.905 79
Source
Corrected Model
Intercept
PULSE
PERFTRK
PERBFAT
STPHIDAY
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .836 (Adjusted R Squared = .237)a. 
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APPENDIX N 
 
General Linear Model Results 
Sum of Squares 
for 
Tissue Plasminogen Activator 
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Tests of Between-Subjects Effects
Dependent Variable: TPAACT
6.379a 57 .112 .959 .567
32.082 1 32.082 275.020 .000
4.698 44 .107 .915 .610
.054 1 .054 .466 .502
1.386 12 .116 .990 .488
2.566 22 .117
45.469 80
8.945 79
Source
Corrected Model
Intercept
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .713 (Adjusted R Squared = -.030)a. 
 
 
Tests of Between-Subjects Effects
Dependent Variable: TPAACT
6.380a 58 .110 .900 .636
3.104 1 3.104 25.409 .000
.001 1 .001 .008 .932
3.978 44 .090 .740 .803
.047 1 .047 .386 .541
1.385 12 .115 .945 .525
2.565 21 .122
45.469 80
8.945 79
Source
Corrected Model
Intercept
TRIG
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .713 (Adjusted R Squared = -.079)a. 
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APPENDIX O 
 
General Linear Model Results 
Sum of Squares 
for 
Plasminogen Activator Inhibitor – 1 
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Tests of Between-Subjects Effects
Dependent Variable: PAI1
3199.944a 59 54.236 .815 .736
2269.741 1 2269.741 34.107 .000
2753.889 45 61.198 .920 .606
54.136 1 54.136 .813 .377
355.054 13 27.312 .410 .949
1397.500 21 66.548
7422.024 81
4597.444 80
Source
Corrected Model
Intercept
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .696 (Adjusted R Squared = -.158)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: PAI1
3588.863a 60 59.814 1.186 .346
281.311 1 281.311 5.578 .028
388.919 1 388.919 7.712 .012
2852.381 45 63.386 1.257 .295
97.647 1 97.647 1.936 .179
349.896 13 26.915 .534 .876
1008.580 20 50.429
7422.024 81
4597.444 80
Source
Corrected Model
Intercept
BRADBP
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .781 (Adjusted R Squared = .122)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: PAI1
3215.963a 60 53.599 .776 .778
110.166 1 110.166 1.595 .221
16.019 1 16.019 .232 .635
2154.282 45 47.873 .693 .848
37.338 1 37.338 .541 .471
370.715 13 28.517 .413 .947
1381.481 20 69.074
7422.024 81
4597.444 80
Source
Corrected Model
Intercept
TRIG
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .700 (Adjusted R Squared = -.202)a. 
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Tests of Between-Subjects Effects
Dependent Variable: PAI1
3326.846a 60 55.447 .873 .668
4.677 1 4.677 .074 .789
126.902 1 126.902 1.998 .173
2403.918 45 53.420 .841 .694
152.172 1 152.172 2.395 .137
421.738 13 32.441 .511 .892
1270.598 20 63.530
7422.024 81
4597.444 80
Source
Corrected Model
Intercept
BDYFATMS
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .724 (Adjusted R Squared = -.105)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: PAI1
3447.053a 60 57.451 .999 .526
40.994 1 40.994 .713 .409
247.109 1 247.109 4.296 .051
2313.280 45 51.406 .894 .635
213.607 1 213.607 3.714 .068
437.154 13 33.627 .585 .839
1150.390 20 57.520
7422.024 81
4597.444 80
Source
Corrected Model
Intercept
PERFTRK
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .750 (Adjusted R Squared = -.001)a. 
 
Tests of Between-Subjects Effects
Dependent Variable: PAI1
3654.779a 61 59.914 1.208 .333
246.613 1 246.613 4.971 .038
207.726 1 207.726 4.187 .055
65.916 1 65.916 1.329 .263
2470.235 45 54.894 1.106 .419
160.997 1 160.997 3.245 .088
378.082 13 29.083 .586 .836
942.665 19 49.614
7422.024 81
4597.444 80
Source
Corrected Model
Intercept
BRADBP
PERFTRK
AGE
SEX
AGE * SEX
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .795 (Adjusted R Squared = .137)a. 
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Raw Data 
 171
ID Number Age Decade Group Height Weight BMI Waist Girth Gender Medications Rest Ankle SBP
1001 22 2 1 177.5 69.7 22.12 75.6 1 0 118
1002 57 5 2 174 67.9 22.43 75.4 2 0 150
1003 25 2 1 180.4 80.9 24.86 81.9 1 0 134
1004 59 5 2 163 71.6 26.95 82 2 0 124
1005 58 5 2 185.4 100.4 29.21 99.9 1 0 150
1006 40 4 2 180.2 92.5 28.49 95.3 1 0 154
1007 44 4 2 175.8 73.3 23.72 78.8 1 0 140
1008 52 5 2 177.4 72.4 23.01 78.5 1 0 140
1009 33 3 1 177.8 92.9 29.39 97.4 1 0 140
1010 51 5 2 180.7 81.6 24.99 93 1 0 130
1011 24 2 1 195.6 88.6 23.16 83 1 0 152
1012 50 5 2 162.5 75.1 28.44 92 2 0 124
1013 26 2 1 183.5 84.8 25.18 82.9 1 0 114
1014 54 5 2 162.56 55.86 21.14 87.2 2 0 130
1015 48 4 2 171.9 71.4 24.16 84.5 2 0 140
1016 45 4 2 166 57.1 20.72 73 1 0 122
1017 26 2 1 160.6 76.36 29.61 95.1 2 0 112
1018 55 5 2 170 93.3 32.28 101 1 0 160
1019 23 2 1 188 83.8 23.71 75.4 1 0 122
1020 24 2 1 181 66.5 20.30 72.6 1 0 138
1021 66 6 3 153.1 51.8 22.10 72 2 0 136
1022 61 6 3 164.2 70.5 26.15 81 2 0 152
1023 37 3 1 175.9 61.9 20.01 69.1 2 0 120
1024 38 3 1 164.2 56.6 20.99 69.6 2 0 130
1025 42 4 2 184.5 111 32.61 112 1 0 122
1026 50 5 2 168 57.1 20.23 70 2 0 120
1027 47 4 2 165.1 53.2 19.52 64 2 0 116
1028 45 4 2 178.4 90.5 28.44 94.1 1 0 122
1029 52 5 2 177.8 63.2 19.99 68.7 2 0 136
1030 39 3 1 167.6 59.7 21.25 71.7 2 0 136
1031 67 6 3 165 56 20.57 72 2 0 140
1032 53 5 2 163.9 69.4 25.83 72 2 0 134
1033 65 6 3 161.3 55.1 21.18 65.1 2 0 120
1034 63 6 3 160.02 61.5 24.02 72 2 0 120
1035 57 5 2 175.8 80.4 26.01 92.4 1 0 132
1036 31 3 1 173 72 24.06 80 1 0 136
1037 58 5 2 156.2 80.3 32.91 101.4 2 0 152
1038 35 3 1 164.2 63.1 23.40 76.6 2 0 122
1039 25 2 1 183.2 80.5 23.99 82.3 1 0 110
1040 24 2 1 174 75.1 24.81 78.5 1 0 120
1041 25 2 1 185.4 77.3 22.49 73.4 2 0 122
1042 22 2 1 178.5 77.4 24.29 81 1 0 130
1043 43 4 2 175.6 87.3 28.31 82.5 1 0 120
1044 41 4 2 179 70.6 22.03 88 1 0 118
1045 60 6 3 170.2 81.8 28.24 93.5 1 0 130
1046 22 2 1 165.1 60.8 22.31 76 2 0 130
1047 33 3 1 174.5 76.5 25.12 82.5 1 0 128
1048 34 3 1 175.3 78 25.38 75.5 1 0 132
1049 45 4 2 174 66.4 21.93 73.8 2 0 130
1050 63 6 3 168 68.4 24.23 80 2 0 138
1051 21 2 1 157.5 52.9 21.33 67 2 0 120
1052 60 6 3 183 83.4 24.90 95 1 0 146
1053 23 2 1 166.5 57.5 20.74 69.1 2 0 118
1054 24 2 1 168 66.3 23.49 74.5 2 0 136
1055 24 2 1 167.5 55.1 19.64 67 2 0 140
1056 71 7 3 183 82.2 24.55 96.1 1 0 142
1057 22 2 1 162.5 49.2 18.63 65 2 0 128
1058 45 4 2 164.5 64.1 23.69 79.5 2 0 130
1059 31 3 1 159.1 58 22.91 68.4 2 0 124
1060 34 3 1 177.8 85.5 27.05 81.6 1 0 140
1061 62 6 3 162.3 64.3 24.41 80.1 2 0 136
1062 77 7 3 170 66.1 22.87 78.8 2 0 180
1063 45 4 2 175.5 95.8 31.10 97.5 1 0 150
1064 52 5 2 178.3 75.6 23.78 82.6 1 0 142
1065 42 4 2 162 76.8 29.26 91.3 2 0 130
1066 45 4 2 157.5 55.4 22.33 69.4 2 0 134
1067 73 7 3 171.4 80.8 27.50 96.3 1 0 156
1068 89 7 3 166.6 59.9 21.58 81.5 1 0 148
1069 71 7 3 181.6 75.7 22.95 87.4 2 0 122
1070 31 3 1 176.1 64.8 20.90 75 1 0 126
1071 47 4 2 170 86.6 29.97 93 2 0 148
1072 84 7 3 177.6 82.1 26.03 94.1 1 0 130
1073 30 3 1 164.6 78.4 28.94 90.4 2 0 130
1074 78 7 3 168.1 77.1 27.28 83.5 2 0 156
1075 53 5 2 175.2 79.7 25.97 89.6 1 0 144
1076 60 6 3 185.5 107.9 31.36 104.6 1 0 144
1077 71 7 3 177.2 76 24.20 85.7 1 0 140
1078 60 6 3 188 92.6 26.20 90.4 1 0 140
1079 37 3 1 165.7 93 33.87 104.3 2 0 106
1080 73 7 3 171 93.1 31.84 94.4 2 0 150
1081 81 7 3 157.5 75.5 30.44 95.4 2 0 144
1082 75 7 3 182 70.8 21.37 79 1 0 192  
 172
ID Number Rest Brachial SBP Rest ABI Rest Brachial DBP Rest Pulse PA Score SAM Low Cadence Steps Medium Cadence S
1001 106 1.11 56 46 5 3239 3394
1002 126 1.19 84 60 5 5900 4752
1003 116 1.16 64 61 7 1881 2098
1004 114 1.09 76 65 5 1691 2405
1005 124 1.21 70 54 3 1946 2520
1006 126 1.22 78 42 2 2130 2816
1007 114 1.23 76 55 7 24894 13833
1008 116 1.21 70 58 7 5405 5948
1009 120 1.17 64 60 3 4305 4983
1010 112 1.16 74 56 7 2899 4111
1011 122 1.25 79 45 6 1115 758
1012 107 1.16 71 55 3 4321 3534
1013 114 1.00 64 68 6 1212 1153
1014 104 1.25 71 76 7 2601 4028
1015 128 1.09 80 51 5 3172 3112
1016 106 1.15 69 45 6 2248 2533
1017 102 1.10 69 54 3 3673 2440
1018 132 1.21 84 49 7 1627 1628
1019 110 1.11 68 53 7 2860 2221
1020 123 1.12 70 50 7 4983 4125
1021 115 1.18 74 58 6 2125 2334
1022 138 1.10 84 54 5 2787 4721
1023 103 1.17 65 42 7 12350 15356
1024 102 1.27 68 48 7 3811 4645
1025 99 1.23 64 64 3 3275 3368
1026 94 1.28 52 45 7 7686 11656
1027 100 1.16 60 51 3 3069 5266
1028 104 1.17 62 41 7 5110 6675
1029 110 1.24 70 53 7 10287 16037
1030 116 1.17 74 48 7 5829 8859
1031 120 1.17 70 64 3 2854 1611
1032 128 1.05 74 48 3 5938 7273
1033 118 1.02 76 58 7 6264 6474
1034 112 1.07 68 58 3 3176 4167
1035 126 1.05 77 58 6 1580 1586
1036 110 1.24 68 50 7 3275 5640
1037 129 1.18 82 72 7 11137 13096
1038 102 1.20 64 54 6 6178 6902
1039 105 1.05 54 50 7 2480 2206
1040 108 1.11 68 49 6 2369 3253
1041 101 1.21 72 56 6 2777 2125
1042 116 1.12 70 56 6 3173 4380
1043 116 1.03 60 64 7 11342 15148
1044 98 1.20 64 47 6 15985 14695
1045 110 1.18 64 67 7 8253 10457
1046 108 1.20 68 64 7 6077 6473
1047 120 1.07 72 47 7 12782 21275
1048 116 1.14 70 56 6 10649 15000
1049 110 1.18 64 60 7 3275 4262
1050 116 1.19 66 62 3 14490 14859
1051 107 1.12 74 92 6 9567 9445
1052 124 1.18 78 52 7 5087 19021
1053 110 1.07 70 74 7 6435 6467
1054 116 1.17 75 58 6 6329 5757
1055 114 1.23 74 72 5 5767 4883
1056 124 1.15 81 53 7 7749 13164
1057 106 1.21 64 64 3 10402 9965
1058 108 1.20 64 55 6 9209 13349
1059 106 1.17 60 58 7 9632 26245
1060 129 1.09 84 59 6 9415 15868
1061 126 1.08 84 76 2 12894 13520
1062 150 1.20 78 73 3 8500 8832
1063 124 1.21 80 64 6 8404 10654
1064 122 1.16 84 50 7 11248 15081
1065 106 1.23 74 53 7 10558 9196
1066 126 1.06 74 53 7 8770 9351
1067 142 1.10 80 66 6 11284 15688
1068 143 1.03 75 54 3 9194 10641
1069 108 1.13 66 55 3 7656 8496
1070 119 1.06 68 64 7 12352 15139
1071 120 1.23 76 74 3
1072 128 1.02 78 63 3 15700 16173
1073 118 1.10 82 78 3 8617 11727
1074 144 1.08 86 74 1 2646 10449
1075 136 1.06 82 62 4 3992 6044
1076 124 1.16 70 62 3 7343 9103
1077 118 1.19 64 47 3 4554 14338
1078 128 1.09 82 65 1 10696 16341
1079 106 1.00 66 59 3 7334 7960
1080 136 1.10 82 66 3 16262 20837
1081 134 1.07 74 88 3 7272 7319
1082 177 1.08 84 51 6 9996 11029  
 173
ID Number SAM High Cadence Steps SAM Total Steps SAM Sedentary Time SAM Low Cadence Time
1001 7584 14217 1864 618
1002 3130 13782 1521 957
1003 3514 7493 2363 357
1004 4479 8575 2329 297
1005 4969 9435 3169 328
1006 2199 7145 2272 312
1007 26333 65060 6781 1659
1008 11464 22817 2698 1020
1009 6626 15914 3036 841
1010 4212 11222 3542 465
1011 1539 3412 2544 175
1012 15096 22951 2977 836
1013 3031 5396 2466 252
1014 8252 14881 1972 440
1015 6079 12363 2053 547
1016 7698 12479 2198 397
1017 4498 10611 2061 561
1018 5089 8344 2354 231
1019 4571 9652 2142 481
1020 33277 42385 3432 822
1021 7386 11845 2276 334
1022 5433 12941 2034 436
1023 9655 37361 4540 1747
1024 6402 14858 1847 631
1025 12180 18823 3336 496
1026 9341 28683 3340 1105
1027 2713 11048 2960 480
1028 12565 24350 4602 717
1029 18689 45013 3223 1406
1030 12388 27076 2690 871
1031 964 5429 884 443
1032 7706 20917 2824 918
1033 11185 23923 4144 1049
1034 4786 12129 2051 430
1035 7993 11159 2347 234
1036 12175 21090 3220 555
1037 17166 41399 7013 2014
1038 8310 21390 2700 986
1039 6925 11611 4882 547
1040 4630 10252 2115 432
1041 4561 9463 2153 456
1042 7730 15283 4562 591
1043 29208 55698 7041 1726
1044 11498 42178 6442 2598
1045 19067 37777 15654 1156
1046 18598 31148 8086 1260
1047 35824 69881 6067 2080
1048 11782 37431 8206 1676
1049 2152 9689 2986 477
1050 18205 47554 8201 2165
1051 11623 30635 6238 1746
1052 12426 36534 24362 739
1053 11640 24542 4064 1045
1054 8258 20344 4075 1164
1055 9913 20563 7571 981
1056 22964 43877 6284 1176
1057 13079 33446 8410 1683
1058 18102 40660 7475 1589
1059 37065 72942 6590 1389
1060 10984 36267 7617 1488
1061 9104 35518 7068 2158
1062 10711 28043 8294 1277
1063 10167 29225 7912 1530
1064 28859 55188 6908 1710
1065 6786 26540 7617 1794
1066 21418 39539 7754 1437
1067 11840 38812 7651 1489
1068 3684 23519 8055 1374
1069 16014 32166 8012 1308
1070 7557 35048 5708 1973
1071 0
1072 5997 37870 9204 2178
1073 10273 30617 9086 1363
1074 12923 26018 4539 413
1075 4603 14639 3120 663
1076 28460 44906 7770 1212
1077 17982 36874 2638 670
1078 11277 38314 7527 1606
1079 5182 20476 8201 1285
1080 12930 50029 6338 2409
1081 3055 17646 8586 974
1082 14312 35337 7685 1641  
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ID Number SAM Medium Cadence Time SAM High Cadence Time SAM Total Activity Time Monitoring Time Period Days
1001 154 167.00 939 2803 2
1002 226 71 1254 2775 2
1003 96 81 534 2897 2
1004 113 88 498 2827 2
1005 117 104 549 3718 3
1006 132 52 496 2768 2
1007 633 603 2895 9676 7
1008 274 263 1557 4255 3
1009 224 158 1223 4259 3
1010 184 110 759 4301 3
1011 34 38 247 2791 2
1012 164 261 1261 4238 3
1013 50 69 371 2837 2
1014 177 190 807 2779 2
1015 142 131 820 2873 2
1016 117 157 671 2869 2
1017 116 87 764 2825 2
1018 78 89 398 2752 2
1019 102 101 684 2826 2
1020 188 676 1686 5118 4
1021 110 119 563 2839 2
1022 213 115 764 2798 2
1023 724 211 2682 7222 5
1024 217 152 1000 2847 2
1025 158 234 888 4224 3
1026 529 231 1865 5205 4
1027 240 69 789 3749 3
1028 311 245 1273 5875 4
1029 725 410 2541 5764 4
1030 407 245 1523 4213 3
1031 80 24 547 1431 1
1032 336 164 1418 4242 3
1033 297 237 1583 5727 4
1034 193 101 724 2775 2
1035 76 139 449 2796 2
1036 247 283 1085 4305 3
1037 603 380 2997 10010 7
1038 318 187 1491 4191 3
1039 101 152 800 5682 4
1040 144 104 680 2795 2
1041 99 104 659 2812 2
1042 199 172 962 5524 4
1043 693 579 2998 10039 7
1044 685 259 3542 9984 7
1045 475 439 2070 17724 12
1046 298 363 1921 10007 7
1047 962 819 3861 9928 7
1048 688 308 2672 10878 8
1049 194 54 725 3711 3
1050 697 357 3219 11420 8
1051 443 267 2456 8694 6
1052 842 307 1888 26250 18
1053 306 260 1611 5675 4
1054 273 176 1613 5688 4
1055 228 206 1415 8986 6
1056 592 507 2275 8559 6
1057 463 293 2439 10849 8
1058 598 395 2582 10057 7
1059 1151 864 3404 9994 7
1060 725 273 2486 10103 7
1061 625 207 2990 10058 7
1062 414 224 1915 10209 7
1063 492 249 2271 10183 7
1064 690 578 2978 9886 7
1065 421 167 2382 9999 7
1066 427 438 2302 10056 7
1067 722 289 2500 10151 7
1068 498 97 1969 10024 7
1069 389 324 2021 10033 7
1070 695 201 2869 8577 6
1071
1072 769 157 3104 12308 9
1073 754 391 2508 11594 8
1074 452 339 1204 5743 4
1075 272 119 1054 4174 3
1076 413 567 2192 9962 7
1077 611 462 1743 4381 3
1078 746 302 2654 10181 7
1079 366 123 1774 9975 7
1080 971 309 3689 10027 7
1081 344 81 1399 9985 7
1082 506 346 852 2493 2  
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ID Number Steps/day Min/day stploday stpmdday stphiday minloday minmdday minhiday sedday
1001 7304 482 1664 1744 3896 317 79 86 958
1002 7152 651 3062 2466 1624 497 117 37 789
1003 3725 265 935 1043 1747 177 48 40 1175
1004 4368 254 861 1225 2281 151 58 45 1186
1005 3654 213 754 976 1925 127 45 40 1227
1006 3717 258 1108 1465 1144 162 69 27 1182
1007 9682 431 3705 2059 3919 247 94 90 1009
1008 7722 527 1829 2013 3880 345 93 89 913
1009 5381 414 1456 1685 2240 284 76 53 1026
1010 3757 254 971 1376 1410 156 62 37 1186
1011 1760 127 575 391 794 90 18 20 1313
1012 7798 428 1468 1201 5129 284 56 89 1012
1013 2739 188 615 585 1538 128 25 35 1252
1014 7711 418 1348 2087 4276 228 92 98 1022
1015 6197 411 1590 1560 3047 274 71 66 1029
1016 6263 337 1128 1271 3864 199 59 79 1103
1017 5409 389 1872 1244 2293 286 59 44 1051
1018 4366 208 851 852 2663 121 41 47 1232
1019 4918 349 1457 1132 2329 245 52 51 1091
1020 11925 474 1402 1161 9363 231 53 190 966
1021 6008 286 1078 1184 3746 169 56 60 1154
1022 6660 393 1434 2430 2796 224 110 59 1047
1023 7449 535 2462 3062 1925 348 144 42 905
1024 7515 506 1928 2349 3238 319 110 77 934
1025 6417 303 1116 1148 4152 169 54 80 1137
1026 7935 516 2126 3225 2584 306 146 64 924
1027 4244 303 1179 2023 1042 184 92 27 1137
1028 5968 312 1252 1636 3080 176 76 60 1128
1029 11245 635 2570 4006 4669 351 181 102 805
1030 9255 521 1992 3028 4234 298 139 84 919
1031 5463 550 2872 1621 970 446 81 24 890
1032 7101 481 2016 2469 2616 312 114 56 959
1033 6015 398 1575 1628 2812 264 75 60 1042
1034 6294 376 1648 2162 2484 223 100 52 1064
1035 5747 231 814 817 4117 121 39 72 1209
1036 7054 363 1095 1887 4072 186 83 95 1077
1037 5956 431 1602 1884 2469 290 87 55 1009
1038 7349 512 2123 2371 2855 339 109 64 928
1039 2943 203 629 559 1755 139 26 39 1237
1040 5282 350 1221 1676 2385 223 74 54 1090
1041 4846 337 1422 1088 2336 234 51 53 1103
1042 3984 251 827 1142 2015 154 52 45 1189
1043 7989 430 1627 2173 4190 248 99 83 1010
1044 6083 511 2306 2119 1658 375 99 37 929
1045 3069 168 671 850 1549 94 39 36 1272
1046 4482 276 874 931 2676 181 43 52 1164
1047 10136 560 1854 3086 5196 302 140 119 880
1048 4955 354 1410 1986 1560 222 91 41 1086
1049 3760 281 1271 1654 835 185 75 21 1159
1050 5996 406 1827 1874 2296 273 88 45 1034
1051 5074 407 1585 1564 1925 289 73 44 1033
1052 2004 104 279 1043 682 41 46 17 1336
1053 6227 409 1633 1641 2954 265 78 66 1031
1054 5150 408 1602 1457 2091 295 69 45 1032
1055 3295 227 924 782 1589 157 37 33 1213
1056 7382 383 1304 2215 3864 198 100 85 1057
1057 4439 324 1381 1323 1736 223 61 39 1116
1058 5822 370 1319 1911 2592 228 86 57 1070
1059 10510 490 1388 3782 5341 200 166 124 950
1060 5169 354 1342 2262 1566 212 103 39 1086
1061 5085 428 1846 1936 1303 309 89 30 1012
1062 3956 270 1199 1246 1511 180 58 32 1170
1063 4133 321 1188 1507 1438 216 70 35 1119
1064 8039 434 1638 2197 4204 249 101 84 1006
1065 3822 343 1521 1324 977 258 61 24 1097
1066 5662 330 1256 1339 3067 206 61 63 1110
1067 5506 355 1601 2225 1680 211 102 41 1085
1068 3379 283 1321 1529 529 197 72 14 1157
1069 4617 290 1099 1219 2298 188 56 47 1150
1070 5884 482 2074 2542 1269 331 117 34 958
1071
1072 4431 363 1837 1892 702 255 90 18 1077
1073 3803 311 1070 1457 1276 169 94 49 1129
1074 6524 302 663 2620 3240 104 113 85 1138
1075 5050 364 1377 2085 1588 229 94 41 1076
1076 6491 317 1061 1316 4114 175 60 82 1123
1077 12120 573 1497 4713 5911 220 201 152 867
1078 5419 375 1513 2311 1595 227 106 43 1065
1079 2956 256 1059 1149 748 186 53 18 1184
1080 7185 530 2335 2992 1857 346 139 44 910
1081 2545 202 1049 1056 441 140 50 12 1238
1082 20411 492 5774 6371 8267 292 200 200 948  
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ID Number BMD (g/cm2) % Total Body Fat % Fat - Leg % Fat - Arms % Fat - Trunk T. Mass - Total Body T. Mass - Leg
1001 1.161 11.1 13.3 9.5 8.8 70984.4 13574.1
1002 1.002 30 37.6 29.5 25.1 67943.5 15792.7
1003 1.272 12.6 12.9 10.1 12 80378.3 16751.2
1004 1.031 39.3 46.1 38.5 37 71799.4 25339.9
1005 1.198 24.8 26.6 21.4 24.8 101986.6 33461.3
1006 1.048 25.3 31.7 22.9 22.2 93526.4 20606.4
1007 1.381 9.4 8.9 9.8 8.2 72057.9 22445.7
1008 1.191 16.8 18.4 16.7 15.3 72404.3 24088.6
1009 1.185 23.3 20 17.9 26.6 92930.7 18666.3
1010 1.04 22.4 24.4 19.6 22 80115.3 15841.2
1011 1.396 11.6 12.5 10.6 10.3 88720.6 30204.6
1012 0.966 35.1 33.15 37.1 37.4 77185.1 23648.8
1013 1.189 19.6 21 15.3 19.4 84604.8 27715.7
1014 1 29.6 38.7 35.7 22.5 56406.5 20959
1015 1.149 29.5 34.6 34.2 26.3 71830.9 24487.8
1016 0.954 18.6 23.7 16.7 15.6 57974.6 18091.5
1017 0.978 41.3 44.6 36.3 42.1 78025.2 27944.3
1018 1.326 28.3 30.4 20.8 29.5 92408 28636.3
1019 1.248 15 14.6 11.9 15.4 86535.7 27279.8
1020 1.237 9.3 10.3 9.7 7.2 67215.1 20874.3
1021 0.964 26.8 28.1 38.6 24.5 52891 18072.7
1022 1.126 33.7 38.8 35.1 31.5 70393.3 14876.2
1023 1.207 21.6 30.2 24 15.2 61904.6 21761.6
1024 1.152 15.3 21.8 12.9 10.7 58419.9 19748.9
1025 1.145 36.8 32 32.1 41.8 113686.7 34171.5
1026 1.132 22 28 22.1 16.3 57727.1 23199.4
1027 1.041 25 35.5 26.9 16.4 53284.2 20521.2
1028 1.029 19.5 16.3 16.5 22.3 90687.9 28617.2
1029 1.118 20.3 27.2 24.8 14.6 62849.5 69762.4
1030 1.106 25 31.2 32.8 18.6 60819.4 22729.7
1031 1.027 31.2 35 39.8 28.2 55811.5 18848
1032 1.05 33 39.5 33 29 68195.8 27681.2
1033 0.97 33.1 43.3 42.8 24.7 55586 20899.5
1034 0.99 39.8 49.2 49 33.7 58699.7 21635.2
1035 1.347 16.1 18.9 12.5 14.4 80563.7 27706.4
1036 1.241 10.8 10.9 9.6 9.7 72750.9 24716.3
1037 0.946 36 33.7 35.4 39.2 81060.5 12306
1038 1.015 22.6 29.9 23 17.1 63058.6 23003
1039 1.234 11.3 11.3 10.7 10.4 79732.2 27467.8
1040 1.284 17.2 20.1 15.5 15.2 74506 25142.3
1041 1.179 30.6 37.8 29.9 25.2 77501.7 31691.2
1042 1.141 22.4 28.5 22.5 17.9 76956.7 27786.9
1043 1.251 10.6 10.4 8.5 10.5 86301.8 27268.3
1044 1.126 15.3 16 13.6 14.5 70181.4 23096.8
1045 1.353 19.6 17.6 15.2 22 82428.3 25399
1046 1.093 25.8 31.6 29.5 21.5 59113.8 20347.1
1047 1.068 13.1 13.4 12.1 12.1 77174.6 28177.3
1048 1.268 13.1 14.8 11 11.6 79609.7 26040.5
1049 1.235 28 34.9 34.5 22.4 66776.2 24927.2
1050 1.004 31.7 39.5 36.1 26.2 68890.3 24479.1
1051 1.144 29.1 35.3 29.7 25.7 52504.5 18980.7
1052 1.26 21.9 18.7 21.1 24.3 82716.3 26339.8
1053 1.09 20.3 26.7 26.1 13.2 57548.3 22356.1
1054 1.096 26.3 32.8 30.6 20.9 67462 24932
1055 1.161 23.4 32.4 28.3 15.2 53479.2 20689.2
1056 1.246 22.9 21.6 19.9 24.7 81996.3 25097.7
1057 0.968 20.5 26.3 21.6 15.8 49762 17869.8
1058 1.194 30.8 35.7 32.8 28 64301.8 15546.3
1059 1.15 26.2 31.9 24.5 23.3 57967.8 20788.5
1060 1.114 21.5 22.2 17.1 22.2 85453.9 28295.1
1061 1.041 38.6 39.9 45.5 38.5 65779.1 21891.5
1062 0.98 36.4 45.2 40 30.9 66762.4 24698.6
1063 1.208 25 25.7 22.3 25.7 97268.7 33336.8
1064 1.055 13.3 14.6 11 11.7 75071.3 25104.2
1065 1.098 32 29.1 30.2 35.3 78593.3 25002.3
1066 1.08 25.5 28.2 29 23.1 54909.4 20587.8
1067 1.17 25.6 22.3 23.1 29.1 80254.3 25313.9
1068 1.07 19.8 18.9 20.3 20.1 59972 18777
1069 1.242 35.8 36.7 39.8 36.4 75630.7 24175.6
1070 1.147 11.3 14.3 8.5 8.2 68062.6 23330.4
1071 1.104 38.9 39.7 41.3 40 86822.7 28417.6
1072 1.12 23.8 26.4 21.3 22.9 83222.5 28312.7
1073 1.002 37.9 35.8 39.8 40.6 77882.1 24912.3
1074 0.945 46.2 50.6 50.5 45.2 78336.9 27876
1075 1.18 26.3 28.5 23.5 26.4 80131.1 25748
1076 1.084 33.9 30.6 31 37.9 109100.5 36316.8
1077 1.118 18.3 19.7 13.2 18.1 77949.9 27472.4
1078 1.138 29.9 29.8 24.7 32 92886.2 27803
1079 1.089 44.1 47.7 41.4 44.3 94471.4 37030
1080 1.058 44 47 45.5 43.9 94261.4 34528.1
1081 0.949 42.5 47.8 45.2 40.3 75468.3 28697.1
1082 1.2 15.4 14.8 14.4 15.5 70408.4 23844.9  
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ID Number  T. Mass - Arms T. Mass - Trunk Body Fat Mass Trunk Fat Mass Triglyceride Cholesterol (mg/dL) HDL (mg/dL)
1001 8730.5 314267.1 9440.9 27655.5 79 145 51
1002 6872.4 30601.8 25546.8 7681.1 57 151 54
1003 10284.6 38034.5 10368.8 4564.1 33 199 68
1004 7572 34575 33099.5 12792.8 62 216 72
1005 11714.2 50976.5 27128.4 12642.2 176 196 39
1006 11490.3 16545 29647.9 3673.0 59 176 50
1007 4499.5 36286.9 6413.2 2975.5 58 150 52
1008 8914.4 34178.3 13322.4 5229.3 75 200 76
1009 10284.7 48274.7 18586.1 12841.1 245 191 30
1010 9302.5 40064.1 19548.1 8814.1 87 172 42
1011 10943 42538.2 11090.1 4381.4 84 166 54
1012 7880.7 41118.8 25586.9 15378.4 112 177 43
1013 10385.9 40667 17767.0 7889.4 136 204 55
1014 5470.5 25976.3 21829.3 5844.7 54 205 111
1015 7540.7 35009.8 24853.5 9207.6 73 157 60
1016 6410.9 29338.9 13740.0 4576.9 88 175 64
1017 6222.8 39486.4 34799.2 16623.8 62 177 54
1018 11036.4 47857.7 28092.0 14118.0 60 125 44
1019 11768 42650.1 12634.2 6568.1 80 178 44
1020 7377.9 34296.2 6923.2 2469.3 22 104 47
1021 5187.5 24441.8 14862.4 5988.2 51 277 69
1022 7378 33558.9 27312.6 10571.1 102 233 55
1023 6675.5 29365 18695.2 4463.5 53 142 62
1024 5876.3 28329 12735.5 3031.2 127 171 61
1025 12816.6 61820.5 36379.7 25841.0 146 161 26
1026 2991.2 24552.3 16163.6 4002.0 50 180 53
1027 5386.4 23386.4 18915.9 3835.4 53 134 43
1028 12394.4 44702 14782.1 9968.5 150 180 42
1029 6173.2 30664.6 17095.1 4477.0 31 230 99
1030 6839.6 27225.2 18975.7 5063.9 39 147 52
1031 6001.7 27109.3 19534.0 7644.8 118 196 58
1032 6400.3 29877.5 26937.3 8664.5 49 162 73
1033 5393.3 25443.8 24068.7 6284.6 58 288 71
1034 5524.2 27009.7 28880.3 9102.3 82 208 65
1035 9687.3 37717.9 15226.5 5431.4 51 135 45
1036 9290 34065.6 7929.8 3304.4 68 195 51
1037 9126.1 42401.3 27317.4 16621.3 154 227 40
1038 6655.4 29182 18854.5 4990.1 42 149 40
1039 10348.7 37131.9 9009.7 3861.7 82 225 53
1040 9387.1 34878 14975.7 5301.5 150 256 48
1041 7953.7 33712.5 29295.6 8495.6 36 145 57
1042 8497.5 35543.2 21932.7 6362.2 63 157 36
1043 13085.5 41724.3 8975.4 4381.1 39 136 53
1044 8224.1 33866.4 11229.0 4910.6 57 175 52
1045 11350.2 40462 14507.4 8901.6 97 159 46
1046 6554.6 28130.7 18680.0 6048.1 76 162 46
1047 8706.6 35721.9 10341.4 4322.3 49 235 75
1048 10301.5 38068.1 11782.2 4415.9 67 205 26
1049 6062.5 30870.7 23304.9 6915.0 47 197 67
1050 8002.9 31701.2 27211.7 8305.7 43 273 95
1051 5274.5 24369 18534.1 6262.8 102 159 46
1052 9822.3 41469.1 15467.9 10077.0 52 193 53
1053 6285.5 24663.9 15365.4 3255.6 71 171 50
1054 7245.1 30330.9 22127.5 6339.2 121 228 39
1055 4982.2 23823.1 17327.3 3621.1 96 192 51
1056 9374 42630.8 17711.2 10529.8 50 232 72
1057 4811.6 22828.4 13087.4 3606.9 44 160 46
1058 4209.3 21096.6 22955.7 5907.0 51 208 71
1059 5691.7 27250 18491.7 6349.3 86 213 65
1060 10494.5 41234 18970.8 9153.9 65 150 43
1061 6729.8 33344.6 26245.9 12837.7 67 331 67
1062 3404.4 31386.8 30176.6 9698.5 100 242 71
1063 11277.5 47573.2 24998.1 12226.3 74 185 43
1064 9737 34953.6 10960.4 4089.6 44 238 68
1065 9193.1 40270.7 22870.7 14215.6 54 161 39
1066 5845 24885.6 15484.5 5748.6 40 163 57
1067 9506.6 40075.4 17896.7 11661.9 73 165 37
1068 7089.4 29388.5 11334.7 5907.1 55 197 54
1069 7549.8 39019.5 27756.5 14203.1 85 189 52
1070 9343.3 29650.1 9733.0 2431.3 34 133 59
1071 9280.8 44231.5 34468.6 17692.6 49 152 49
1072 8935.9 40664 21970.7 9312.1 95 188 33
1073 8273.8 40513.6 27881.8 16448.5 149 168 43
1074 7199.4 39018.1 39638.5 17636.2 121 241 44
1075 9969.8 40048.4 22837.4 10572.8 64 218 49
1076 11876.6 55500.5 33384.8 21034.7 87 155 37
1077 8738.5 37030.1 15356.1 6702.4 56 217 59
1078 7781.8 49737 27680.1 15915.8 121 160 44
1079 8848.6 43756.5 45062.9 19384.1 136 64 38
1080 8611.5 46242.8 44302.9 20300.6 61 220 80
1081 7543.3 34991.6 36073.8 14101.6 137 170 45
1082 8003.2 33719.8 10420.4 5226.6 61 191 80  
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ID Number LDL (mg/dL) L/H Ratio Glucose [CRP] mg/L [TPA]ant [TPA]act [Fibrinogen] [PAI-1]act
1001 78 1.5 74.0 0.6 3.190 0.48 4.860 0.00
1002 86 1.6 88.0 0.8 4.900 0.66 4.433 0.00
1003 124 1.8 95.0 0.2 3.924 0.40 6.793 1.62
1004 132 1.8 94.0 0.6 6.199 0.45 9.724 7.59
1005 122 3.1 94.0 0.8 8.332 0.20 2.956 26.35
1006 114 2.3 79.0 0.2 7.660 0.48 13.350 7.99
1007 86 1.7 85.0 1.3 3.608 0.99 3.625 0.00
1008 109 1.4 92.0 3.4 4.719 0.50 2.806 3.42
1009 112 3.7 86.0 3.2 9.000 0.23 4.250 14.82
1010 113 2.7 100.0 0.4 5.111 1.16 2.978 0.21
1011 95 1.8 86.0 0.2 7.399 0.59 2.267 6.16
1012 112 2.6 70.0 0.4 8.379 0.18 3.991 25.15
1013 122 2.2 76.0 0.4 4.229 0.83 2.245 0.77
1014 83 0.7 60.0 0.3 7.791 0.84 2.827 0.00
1015 82 1.4 49.0 3.9 7.693 0.69 3.280 2.26
1016 93 1.5 70.0 0.2 9.752 0.14 2.913 40.03
1017 111 2.1 82.0 3.7 6.124 0.19 3.129 2.38
1018 69 1.6 82.0 0.9 7.268 0.52 2.892 9.94
1019 118 2.7 82.0 0.4 3.052 0.67 7.849 0.21
1020 53 1.1 67.0 2.5 8.706 0.26 2.676 15.89
1021 198 2.9 77.0 0.5 2.595 1.30 2.827 0.00
1022 158 2.9 73.0 1 13.248 0.38 4.077 24.61
1023 69 1.1 76.0 0.7 3.575 0.45 2.547 5.71
1024 85 1.4 69.0 0.2 8.412 0.50 3.150 2.83
1025 106 4.1 97.0 1.6 2.758 1.01 6.017 0.00
1026 117 2.2 86.0 1.9 4.327 0.86 2.806 0.00
1027 80 1.9 84.0 0.2 4.556 0.84 3.431 0.00
1028 108 2.6 86.0 1.1 8.379 0.36 2.655 8.84
1029 125 1.3 82.0 0.2 6.353 0.78 2.547 0.57
1030 87 1.7 74.0 0.7 4.196 0.72 2.892 1.40
1031 114 2.0 105.0 0.4 7.562 0.73 5.349 5.12
1032 79 1.1 80.0 0.9 5.797 0.35 2.784 8.36
1033 205 2.9 84.0 1.7 9.033 1.00 2.827 1.82
1034 127 2.0 85.0 0.8 41.974 1.09 4.142 0.00
1035 80 1.8 89.0 0.3 22.693 2.61 3.107 1.04
1036 130 2.5 79.0 0.2 4.000 0.70 2.741 2.68
1037 156 3.9 94.0 4.2 9.621 0.27 2.655 14.97
1038 101 2.5 69.0 6.1 2.529 0.62 3.000 0.00
1039 156 2.9 58.0 1.1 8.150 0.79 2.159 0.30
1040 178 3.7 86.0 0.2 5.667 0.81 2.978 3.33
1041 81 1.4 67.0 0.6 7.856 0.79 4.034 0.51
1042 108 3.0 86.0 4.2 7.922 0.19 2.806 24.94
1043 75 1.4 75.0 0.4 5.026 1.017 4.745 0.000
1044 112 2.2 78.0 0.2 6.181 1.263 4.797 0.000
1045 94 2.0 67.0 2 8.968 0.627 4.424 4.085
1046 101 2.2 70.0 2.1 6.006 0.389 5.257 10.770
1047 150 2.0 92.0 0.2 5.554 0.423 2.374 5.934
1048 166 6.4 72.0 0.2 8.265 0.828 2.292 0.042
1049 121 1.8 74.0 0.2 4.248 0.759 3.845 0.597
1050 169 1.8 79.0 0.8 5.503 0.683 5.093 1.918
1051 93 2.0 75.0 0.9 4.725 0.322 3.968 17.904
1052 130 2.5 80.0 1.8 11.454 0.297 4.197 19.066
1053 107 0.5 81.0 0.2 4.374 1.240 5.168 0.000
1054 165 4.2 71.0 0.6 22.777 0.562 4.443 1.786
1055 122 2.4 70.0 0.5 4.022 0.718 3.768 0.000
1056 150 2.1 93.0 1.1 8.340 0.639 4.967 1.072
1057 105 2.3 81.0 1.6 4.549 1.047 4.482 0.000
1058 127 1.8 70.0 1.6 6.583 1.287 5.462 0.359
1059 131 2.0 82.0 0.8 11.629 0.734 4.158 1.046
1060 94 2.2 74.0 0.3 8.014 0.501 3.394 9.290
1061 251 3.7 66.0 0.7 17.052 0.828 4.096 3.530
1062 151 2.1 90.0 1.9 9.028 2.430 4.706 0.000
1063 127 3.0 68.0 2.3 8.692 0.507 3.992 5.141
1064 131 1.9 83.0 0.2 20.417 0.511 4.158 10.241
1065 111 2.8 72.0 3.2 9.822 0.442 5.067 16.847
1066 98 1.7 86.0 0.5 4.399 1.224 3.735 0.121
1067 113 3.1 84.0 0.4 11.880 1.092 4.614 2.552
1068 132 2.4 86.0 0.4 9.028 1.195 6.571 2.288
1069 120 2.3 85.0 0.8 8.868 0.639 5.749 5.538
1070 67 1.1 72.0 6.8 7.512 0.970 5.740 0.000
1071 93 1.9 105.0 0.9 7.361 0.251 4.044 17.957
1072 136 4.1 92.0 3.1 8.667 1.327 5.492 0.000
1073 95 2.2 75.0 0.6 16.611 0.354 5.172 10.505
1074 173 3.9 76.0 1.7 8.592 0.724 5.479 5.802
1075 156 3.2 90.0 1.2 12.132 0.495 5.390 19.013
1076 101 2.7 78.0 2.5 10.000 1.636 4.027 0.000
1077 147 2.5 81.0 0.8 10.972 0.696 4.734 12.276
1078 92 2.1 86.0 1.7 21.346 0.275 7.164 17.877
1079 85 2.2 86.0 10.4 12.282 0.377 5.552 7.784
1080 128 1.6 87.0 0.9 8.893 1.285 4.081 1.786
1081 98 2.2 73.0 71 10.550 0.214 4.680 29.133
1082 99 1.2 77.0 0.2 11.680 0.659 4.057 4.270  
 179
